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1 INTRODUCTION	
Obesity has become a worldwide epidemic with many health consequences such as 
diabetes, hypertension, and cardiovascular diseases. The number of overweight adults 
has reached 40% globally, and the prevalence rates of both overweight and obesity is 
rapidly increasing (World Health Organization, 2017). Excess body fat not only 
influences metabolism and cardiovascular health but also relates to accelerated 
cognitive decline during ageing (Emmerzaal et al., 2015; Prickett et al., 2015; Smith et 
al., 2011). 
The relationship between obesity and cognitive function is the overarching topic of my 
thesis. In order to understand this relationship, it is important to have an optimal 
measurement of obesity, a thorough assessment of cognition, and a sensitive biomarker 
of the brain. 
1.1 Measurements	of	Obesity	
Obesity is defined as an adult with a body mass index (BMI, kg/m2) of at least 30, 
whereas overweight is a BMI of at least 25 (World Health Organization, 2017). BMI is 
calculated as body weight in kilograms divided by the square of body height in meters. 
However, BMI measures global obesity and provides no information about body fat 
distribution; therefore, complementary measures such as waist circumference and waist-
to-hip ratio (WHR) were introduced. 
WHR is calculated as waist circumference divided by hip circumference and provides an 
index of abdominal obesity. Abdominal obesity is defined as a WHR above 0.9 for men 
and above 0.85 for women (World Health Organization, 2011). Abdominal obesity is 
considered as a marker of “dysfunctional adiposity tissue” and an important predictor for 
cardiovascular disease risk (Després and Lemieux, 2006). And for cardiovascular 
disease and metabolic dysfunction, high WHR is considered as a stronger independent 
risk factor than high BMI (World Health Organization, 2011). 
Other measurement such as body composition provides more acute information of body 
fat, but they are more difficult to implement in population studies due to the need for 
special (expensive) equipment and longer measuring time compared to BMI or WHR. 
1.2 Obesity	and	Cognitive	Function	
It has been largely established that obesity in both midlife and late-life increases the risk 
for dementia as well as mild cognitive impairment (MCI) (Fergenbaum et al., 2009; 
Fitzpatrick et al., 2009; Gustafson et al., 2009; Whitmer et al., 2008). A recent meta-
analysis with 19 cohort studies on 589,649 participants showed that midlife (aged 35–65 
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years) obesity increases the risk of dementia (relative risk: 1.33; 95% confidence interval: 
1.08–1.63) (Albanese et al., 2017). However, another recent retrospective study of over 
two million people in the UK reported a lower risk of developing dementia later in life for 
midlife global obesity compared to normal weight (Qizilbash et al., 2015). Interestingly, 
two studies reported detrimental effects of abdominal obesity on dementia, but lower or 
no effect was found for global obesity (Gustafson et al., 2009; Whitmer et al., 2008). 
These mixed results might be explained by reverse causation due to weight loss at the 
preclinical stage of dementia (Gustafson, 2015; Kivimäki et al., 2018). The latter is 
commonly seen in observational studies because of insufficient follow-up time periods 
(Kivimäki et al., 2018). Therefore, a well-characterized sample and sufficient follow-up 
time are important in observational studies investigating the link between obesity and 
cognition. 
Additionally, conflicting findings among studies may be due to methodological 
differences (Kullmann et al., 2015; Willette and Kapogiannis, 2015). For instance, BMI 
was often used as an index for obesity, while waist circumference, WHR, or direct 
measures of fat mass were also used in some studies; many studies used continuous 
measurements of BMI or WHR to indicate obesity, whereas others used categorical 
assessments. Combining measures of global and abdominal obesity, for example BMI 
and WHR, would be more comprehensive than using only one measure. Furthermore, 
these measures are easy to implement in a clinical or experimental setting. 
1.3 Obesity	and	the	Human	Brain	
To further understand how obesity affects cognitive function, it is important to assess 
obesity-related brain structural changes. Evidence suggests that obesity leads to 
multiple physiological changes, which in turn can affect brain tissue and neuroplasticity 
(O’Brien et al., 2017; Pugazhenthi et al., 2016). Indeed, numerous studies have 
examined the link between obesity and the human brain in vivo. 
1.3.1 Obesity	and	brain	macrostructure	
In recent years, excess body fat has been related to decreased total brain volume and 
regional grey and white matter volume in both young and older adults (Willette and 
Kapogiannis, 2015). The negative association of obesity with grey matter volume is more 
pronounced than with white matter; there are consistent findings on obesity-related 
volumetric declines in the grey matter of both frontal lobe and prefrontal cortex (for review, 
see Willette and Kapogiannis, 2015). 
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However, studies evaluating global or regional white matter volume have produced 
conflicting or non-replicable findings. For instance, in a prospective longitudinal study, 
152 older participants (aged 56–86 years) were assessed for obesity (measured with 
BMI and waist circumference) and regional brain atrophy as measured by magnetic 
resonance imaging (MRI). After a period of up to 10 years, a steeper decline of temporal 
white matter volume was found for higher central obesity (waist circumference) but not 
for global obesity (BMI) (Driscoll et al., 2012). In a study comparing 23 morbidly obese 
and 22 non-obese healthy volunteers, obese subjects had lower global white matter 
volumes than control subjects (Karlsson et al., 2013). On the contrary, a cross-sectional 
study examined 95 older females (aged 52–92 years) and found increased volume in left 
temporal and right orbital frontal white matter with increased BMI (Walther et al., 2010). 
Another longitudinal study that examined 347 elderly people (baseline mean age 60±7.8 
years) approximately 5 years apart observed no association of BMI with white matter 
volume (Bobb et al., 2014). 
One reason for these conflicting findings is that “mere” volumetric measures in the white 
matter may not provide reliable information of its properties. Consequently, other 
measures of the white matter have been introduced to provide additional information. 
1.3.2 Obesity	and	brain	microstructure	
One widely used MRI technique to evaluate the white matter is diffusion-weighted 
imaging (DWI), which assesses the microstructural architecture and is considered to 
produce more consistent results (Willette and Kapogiannis, 2015). One argument in 
favour for this hypothesis is that many studies have consistently found that high body fat 
predicted low directional property of the white matter (Kullmann et al., 2015; Willette and 
Kapogiannis, 2015). More details about DWI and how to measure the directional property 
of the white matter will be discussed in section 1.5. In the present section I will focus on 
recent findings relating obesity to white matter microstructure. 
Although many studies reported obesity is associated with white matter microstructure, 
the association was found in diverse regions and partially restricted to either men or 
women (for review, see Kullmann et al., 2015). Most available studies had a small or 
medium sample size (n = 15–155) and reported negative correlations between 
directional property and body fat in different, not necessarily overlapping, white matter 
tracts in which the most commonly reported area is the corpus callosum (Bettcher et al., 
2013; Bolzenius et al., 2015; Karlsson et al., 2013; Kullmann et al., 2016; Marks et al., 
2010; Mueller et al., 2011; Ryan and Walther, 2014; Shott et al., 2015; Stanek et al., 
2011; Verstynen et al., 2012; Xu et al., 2013; Yau et al., 2014). A recent study of 268 
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participants (mean age 46±16 years) with a voxel-wise data-driven approach showed a 
negative association of BMI with directional property in most of the long association fibres 
(Papageorgiou et al., 2017); it has shown more affected white matter regions than the 
above-mentioned studies with smaller sample sizes. However, in a recent observational 
study of 168 healthy participants (aged 40–62 years) evaluating the link between waist 
circumference and white matter microstructure, central obesity was associated with, for 
the first time, more directed property in the white matter (Birdsill et al., 2017). 
These mixed findings might be explained by methodological difference among studies, 
for instance, whether demographic confounders and obesity comorbidities have been 
taken into account. On the other hand, a general rather small to medium sample size 
limits the use of data-driven analyses considering multiple testing issue in whole brain 
voxel-wise analysis. Thus, in order to yield more reliable, replicable, and consistent 
results, increasing statistical power with bigger samples might be beneficial to investigate 
the link between obesity and white matter microstructure. 
1.3.3 Neuroinflammation	and	hippocampus	in	obesity.	
There are several mechanisms underlying obesity-associated cognitive impairment and 
brain structural changes. One pathway is that excess body fat could cause peripheral 
inflammation, which leads to insulin resistance and type 2 diabetes (Pugazhenthi et al., 
2016). Insulin resistance and dyslipidaemia can result in dysfunction of the central 
nervous system, for example compromised functioning of the hippocampus (O’Brien et 
al., 2017). 
The hippocampus is highly susceptible to degenerative processes. During the healthy 
ageing process, the hippocampus shows an accelerated shrinkage after age 60 years 
(Pfefferbaum et al., 2013; Raz et al., 2010). A number of studies examined the 
relationship between obesity and the hippocampus. The results are inconclusive: a 
negative association between obesity and hippocampal volume was found in some 
cross-sectional studies (Debette et al., 2011; Raji et al., 2010; Taki et al., 2008), whereas 
other groups found a positive association in a similar setting (Widya et al., 2011) or no 
association in a longitudinal setting (Bobb et al., 2014; Debette et al., 2011; Driscoll et 
al., 2012). 
These inconsistent results might be explained by the fact that subdivisions of the 
hippocampus (cornu ammonis fields [CA1–4], the dentate gyrus [DG], and the subiculum) 
not only have distinct functional properties, but also they are affected by ageing 
differently (de Flores et al., 2015). For example, the DG is related to pattern separation, 
whereas the CA1 and CA3 are involved in navigation (Deng et al., 2010; Strien et al., 
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2009; Yassa and Stark, 2011). In a study of 129 healthy participants (aged 18–85 years), 
the effect of healthy ageing on the hippocampal subfields was examined. Only the DG 
(including CA4) and the subiculum volumes showed an association with age, while the 
volumes of CA1–3 did not (Malykhin et al., 2017). Due to the distinct functions and 
different vulnerabilities in hippocampal subfields, it is important to examine the subfields 
separately when relating them to cognitive function. Additionally, because of the above-
mentioned susceptibility as well as neurogenesis ability (Eriksson et al., 1998), 
hippocampus is often a key target in plasticity-enhancing intervention studies. 
1.4 Candidate	Interventions	Reversing	Obesity-Induced	Effects	
Several studies indicate that lifestyle interventions such as dietary modification and 
physical exercise can be effective to combat obesity and may potentially improve 
cognitive functions (Siervo et al., 2011). A recent meta-analysis which included 13 
longitudinal studies and 7 randomised controlled trials on 1019 participants showed that 
weight loss introduced by bariatric surgery, dietary modification, and/or physical activity 
was associated with improvement in cognition (Veronese et al., 2017). Moreover, in a 
large double-blind randomised controlled trial of 2645 participants, a 2-year intervention 
of diet, exercise, and cognitive training resulted in higher scores in a neuropsychological 
test battery compared to the control group (Ngandu et al., 2015). Among these 
interventional methods, dietary modification is non-invasive and easy to carry out. 
Additionally, obesity is mainly caused by overeating of palatable hyper-caloric food which 
are usually high in saturated fat. Saturated fat has been associated with cognitive decline 
as indicated by a systematic review of 12 observational studies (Barnard et al., 2014). 
On the contrary, other dietary nutrients such as omega-3 fatty acids and flavonoids are 
considered to be beneficial for the central nerve system due to their anti-inflammatory or 
anti-oxidative properties (for review, see Gómez-Pinilla, 2008). Flavonoid is one type of 
food-derived polyphenols which are the secondary metabolites of plants (Manach et al., 
2004). 
Recently, another polyphenol agent resveratrol has come into research focus. It can be 
found in variety of plants such as red grapes, blueberries, and peanuts (Baur et al., 2006). 
A meta-analysis from data of 11 randomised controlled trials suggests that resveratrol 
could modulate glucose metabolism and insulin sensitivity (Liu et al., 2014). And there 
are some evidence suggested that resveratrol is associated with improved cognitive 
functions (Huhn et al., 2015; Marx et al., 2018). For example, in a randomised controlled 
trial, 23 overweight participants completed 26 weeks of resveratrol intake (200 mg/day) 
whereas 23 matched participants received a placebo. An increase in memory 
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performance, increased functional connectivity in the hippocampus, and decreased 
glycated haemoglobin (HbA1c), and decreased body fat was observed in the intervention 
group (Witte et al., 2014). A randomised controlled clinical trial of 40 MCI patients 
showed similar results in decreased HbA1c and higher functional connectivity between 
right anterior hippocampus and right angular cortex, but no difference was found in 
memory performance (Köbe et al., 2017). However, another randomised controlled trial 
of 80 post-menopausal women showed that 14 weeks of resveratrol intake (150 mg/day) 
improved memory and overall cognition (Evans et al., 2017). 
The reason for such mixed results in cognitive performance might be due to the fact that 
resveratrol does not affect cognition, or it is only effective in healthy ageing population 
(Evans et al., 2017; Witte et al., 2014) but not in patients (Köbe et al., 2017; Turner et 
al., 2015; Zortea et al., 2016) or in younger population (Wightman et al., 2015). Thus, 
replication studies with healthy older adults could help us to understand whether there is 
an effect of resveratrol on cognitive function. 
Notably, most of the above-mentioned studies evaluated memory performance and 
subsequently evaluated the structure and function of the hippocampus. Because the 
hippocampus is important in learning and memory, structural and functional changes 
could lead to impairments in different cognitive domains. Therefore, reliable in vivo 
biomarkers are essential when assessing hippocampal structure and function in free-
living humans. 
1.5 Biomarkers	from	Magnetic	Resonance	Imaging	
1.5.1 High-resolution	MRI	and	its	applications	on	hippocampal	subfields	
Over the last four decades, MRI has become a highly versatile imaging technique to 
evaluate the human brain in vivo. While MRI provides important information on both brain 
structure and function in clinical and preclinical research, there are mutual trade-offs 
among resolution, signal-to-noise ratio (SNR), and acquisition time. Higher image 
resolution can be achieved with longer acquisition time or—at constant acquisition 
time—with reduced SNR. An improvement can be achieved with ultra-high field MRI 
(UHF-MRI) which refers to a static magnetic field equal or higher than 7 Tesla (T). UHF-
MRI has an intrinsically higher SNR and thus can achieve higher spatial resolution at 
similar acquisition time compared to non UHF-MRI (Duyn, 2012; Polders et al., 2011). 
Because of these advantages, UHF-MRI has been intensively used to assess 
hippocampus as subdivisions of the hippocampus become much better differentiable at 
UHF-MRI compared to at 1.5T or 3T MRI (Giuliano et al., 2017; Thomas et al., 2008). 
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This may be highly relevant for studies on ageing and/or neurodegeneration considering 
the subfields’ different functions and susceptibility to damage. 
Figure 1 shows the hippocampal subfields at 7T MRI. Each hippocampal subfield is 
relatively small, and subtle changes and small volumetric differences can be difficult to 
detect with limited spatial resolution at lower (clinical) field strength. UHF-MRI brings the 
possibility to identify pathologic patterns and predict cognitive impairment in vivo. In a 
recent review about on dementia diagnosis at 7T, the authors concluded that undetected 
changes in hippocampal subfields among MCI patients at 3T can be identified at 7T 
(McKiernan and O’Brien, 2017). Thus, 7T MRI might enhance the sensitivity to detect 
subtle changes in the hippocampus related to ageing or after intervention. 
 
Figure 1. Hippocampal subfields image with 7-Tesla (7T) magnetic resonance imaging. 
Abbreviations: L, left, R, right, CA, cornu ammonis fields, DG, the dentate gyrus, TSE, turbo 
spin echo, MP2RAGE, Magnetization-Prepared 2 RApid Gradient Echoes, DWI, diffusion-
weighted imaging. Figure adapted from publication 2 (Huhn et al., 2018). 
Besides volumetric measurements, some studies suggest that parameters derived from 
diffusion-weighted images have added value beyond volumetric assessment of the 
hippocampus while investigating the relation between hippocampus and cognition 
(Carlesimo et al., 2010; den Heijer et al., 2012; Pereira et al., 2014). Before I go into 
detail about these parameters, I will first introduce basic knowledge about diffusion-
weighted images. 
1.5.2 Diffusion-weighted	magnetic	resonance	imaging	
DWI has been used extensively for evaluating the microstructural architecture 
particularly of white matter to detect pathological brain changes at early stages (Van 
Hecke et al., 2016). DWI measures diffusion properties of water molecules. Without the 
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presence of boundaries, free water molecules are in constant random motion which is 
known as isotropic diffusion. However, when there are impermeable boundaries 
restraining the water molecules, the diffusion is direction-dependent and anisotropic. In 
the context of biological tissue, water diffusion is restricted by boundaries such as 
macromolecules, fibres, and membranes. Thus, the measured MRI signal would be 
altered under those circumstances (Van Hecke et al., 2016). DWI can reveal microscopic 
details about the tissue architecture by reflecting diffusion patterns of water molecules. 
The diffusion coefficient values of DWI data are very noisy without applying any models. 
The diffusion tensor model is the most widely used mathematical model to describe these 
values (Basser et al., 1994). The diffusion tensor model is also the theoretical basis for 
the practice of diffusion tensor imaging (DTI) based on DWI. The model has six 
parameters and greatly simplifies the features of directional properties within a voxel 
(Van Hecke et al., 2016). It can be visualised by an ellipsoid model (Figure 2a). Three 
eigenvectors e1, e2, and e3 provide the orientation of the axes, in other words, the 
orientation of a tensor, independently of its size and shape. Three eigenvalues !1, !2, 
and !3 define the radius of the ellipsoid which is the shape and size of a tensor, 
independent of its orientation (Van Hecke et al., 2016). Another important parameter in 
DWI is the “b-value” which reflects the amount of diffusion weighting and how much the 
signal in an image is affected by the water diffusion in the tissue (Van Hecke et al., 2016). 
I will not go into details about the technical backgrounds of b-values. One worthy to know 
information is that a DWI sequence contains one (or several) image(s) without diffusion 
weighting (b = 0) and several dozens of images with diffusion weighting (for example, b 
= 1000 s/mm2) (Figure 2b). There are many metrics can be calculated from DTI model; 
fractional anisotropy (FA) and mean diffusivity (MD) are the most commonly used metrics 
derived from DTI (Figure 2c, d). 
FA, as indicated in the name, measures the degree of anisotropy. It is defined as follows: 
"# = %32%(!) − !), + (!, − !), + (!. − !),!), + !,, + !.,  
FA ranges from 0, which means complete isotropy, to 1, which means diffusion is 
restricted to a single axis. In white matter, the direction of diffusion is influenced strongly 
by the orientation of axons due to the restricted movement of water molecules by the 
lipophilic myelin sheath (Madden et al., 2012; Van Hecke et al., 2016). Therefore, FA 
theoretically can be seen to reflect the directional integrity of large fibre bundles. 
However, in practice the underlying anatomy is more complicated, e.g., the presence of 
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crossing fibre makes the calculation very difficult. It should be kept in mind that FA is 
neither a direct measurement of axons nor myelin. But it has been frequently linked to 
axon count and density (Van Hecke et al., 2016). Thus, to some extent, lower FA could 
indicate a loss of axons, less axonal density, or reduced myelination. 
 
Figure 2. (a), The ellipsoid model for diffusion tensor model; (b), a diffusion sequence 
contains non-diffusion-weighted (b=0) and many diffusion-weighted images in different 
gradient directions; (c) and (d), example parameter maps derived from diffusion tensor 
imaging, note the colour FA map contains information about fibre orientation (colour) and the 
degree of anisotropy (intensity). Abbreviations: DWI, diffusion-weighted imaging, MD, mean 
diffusivity, FA, fractional anisotropy, DEC, direction encoding colour, A–P, anterior to 
posterior, L–R, left to right, I–S, inferior to superior. Modified based on Van Hecke et al. 
(2016). 
MD measures the overall diffusivity within a particular voxel regardless of direction, i.e., 
the average of the eigenvalues. It is defined as follows: 
/0 = !) + !, + !.3  
The higher the MD, the more isotropic is the diffusion. MD is in general low in grey matter 
and high in the ventricles. 
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Besides its value for describing microstructural changes in the white matter, both FA and 
MD are discussed to be more sensitive biomarkers for subtle changes than volumetric 
measures in the grey matter (Douaud et al., 2013; Weston et al., 2015). For example, 
three studies of healthy individuals evaluating the effect of age on the hippocampus 
found that MD better predicts age compared to hippocampal volume and FA (Carlesimo 
et al., 2010; den Heijer et al., 2012; Pereira et al., 2014), two of which also found that 
MD predicts memory performance better than other measures (Carlesimo et al., 2010; 
den Heijer et al., 2012). Besides healthy ageing, in a study of 18 amnestic MCI patients, 
hippocampal MD showed the highest sensitivity (89%) for predicting MCI compared to 
FA (78%) and volume (50%) (Müller et al., 2007). These results suggest that MD or FA 
can provide valuable information in addition to volumetric assessment of the 
hippocampus. 
In summary, it is still not clear about the relationship between obesity and cognitive 
function, and abdominal/central obesity may be more detrimental than general obesity. 
In addition, it is not clear whether obesity is associated with white matter alterations, and 
if such an association exists, whether it is regional specific and how it is connected to 
cognitive function. Further, there are some evidence showing dietary intervention could 
improve cognitive function but not conclusive. That is, if dietary supplement such as 
resveratrol could restore obesity-induced glucose/insulin dysfunction and improve 
cognition and hippocampal structure remain unknown. The current thesis is dedicated to 
contributing more evidence in order to answer those questions. 
2 AIM	OF	THE	THESIS	
The current thesis contains two main aims: 
First, to investigate microstructural variability of regions in the white matter that may be 
associated with obesity, and how these regional differences translate to cognitive 
function. 
Second, to investigate the effect of resveratrol intake on glucose regulation, cognitive 
function, and the structure of hippocampal subfields in a healthy older population. 
3 STUDY	DESIGNS	
To achieve the objectives mentioned above, two studies were performed and included 
in this thesis. 
3.1 Study	1:	Zhang	et	al.,	Neuroimage,	2018	
Study 1 included MRI data of 1255 community-dwelling healthy adults from the LIFE-
Adult study (Leipzig, Germany). I processed the DWI data based on a well-established 
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ENIGMA (Enhancing Neuroimaging Genetics Through Meta Analysis)-DTI protocol 
using FMRIB Software Library (Smith et al., 2004). After diffusion tensor model fitting, I 
performed tract-based spatial statistics (Smith et al., 2006) on FA images and created 
skeletonised FA maps of all subjects. Then I carried out voxel-wise cross-subject whole 
brain analysis of BMI or WHR, respectively, on the FA skeletonised maps. 
To test whether obesity-related white matter difference is related to changes in cognition, 
a number of white matter tracts that were selected. They have been linked to cognitive 
function based on previously published evidence (Borghesani et al., 2013; Gold et al., 
2012; Madden et al., 2009a, 2009b; Ryan and Walther, 2014; Salami et al., 2012). The 
selected regions were: uncinate fasciculus, corpus callosum, anterior thalamic radiation, 
superior and inferior longitudinal fasciculus, and cingulum. The mean FA of each 
individual was extracted in the overlap of these regions with potential clusters where FA 
was significantly related to obesity measures according to voxel-wise analysis. 
Subsequently, mediation analysis was performed to test indirect effects between body 
fat and cognitive performance through variability of FA in these regions. 
3.2 Study	2:	Huhn,	…,	Zhang	et	al.,	Neuroimage,	2018	
To evaluate the effectiveness of resveratrol on glucose regulation and cognitive 
performance, a double-blind, randomised controlled trial was carried out in a group of 60 
healthy older adults (aged 60–78 years) who had no cognitive impairment at the time of 
testing. I assigned them randomly into one of the two treatment groups in equal 
proportions. Subjects were allocated with a web-based randomisation system 
(http://www.randomization.com) and stratified for age (60–70 or >70 years) and sex 
(male or female) to minimise imbalance between groups. Investigators who performed 
outcome assessments and subjects were blinded to the treatment assignment. 
Neuropsychological test scores, blood parameters (glucose and HbA1c), anthropometric 
measures, and neuroimaging at baseline and after six months of intervention were 
collected and assessed. T1-weighted and diffusion-weighted images of the hippocampus 
were acquired using state-of-the-art 7T MRI. The subdivisions of the hippocampus were 
segmented with the FreeSurfer image analysis suite (http://surfer.nmr.mgh.harvard.edu/) 
in a longitudinal stream (Reuter et al., 2012). Six main subfields, namely CA1, CA3, CA4, 
DG, presubiculum, and subiculum were considered for further analysis (Brickman et al., 
2014; Erickson et al., 2011). Both volume and MD values were extracted from the six 
subfields. The effect of resveratrol on HbA1c, cognitive function, and hippocampal 
subfields’ structure were then analysed with multivariate repeated-measures analysis of 
variance (MANOVA).  
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A B S T R A C T
Obesity has been linked with structural and functional brain changes. However, the impact of obesity on brain
and cognition in aging remains debatable, especially for white matter. We therefore aimed to determine the ef-
fects of obesity on white matter microstructure and potential implications for cognition in a well-characterized
large cohort of healthy adults. In total, 1255 participants (50% females, 19–80 years, BMI 16.8–50.2 kg/m2)
with diffusion-weighted magnetic resonance imaging at 3T were analysed. Tract-based spatial statistics (TBSS)
probed whether body mass index (BMI) and waist-to-hip ratio (WHR) were related to fractional anisotropy (FA).
We conducted partial correlations and mediation analyses to explore whether obesity or regional FA were related
to cognitive performance. Analyses were adjusted for demographic, genetic, and obesity-associated confounders.
Results showed that higher BMI and higher WHR were associated with lower FA in multiple white matter tracts
(p< 0.05, FWE-corrected). Mediation analyses provided evidence for indirect negative effects of higher BMI and
higher WHR on executive functions and processing speed through lower FA in ﬁber tracts connecting (pre)frontal,
visual, and associative areas (indirect paths, jßj! 0.01; 99% jCIj> 0). This large cross-sectional study showed that
obesity is correlated with lower FA in multiple white matter tracts in otherwise healthy adults, independent of
confounders. Moreover, although effect sizes were small, mediation results indicated that visceral obesity was
linked to poorer executive functions and lower processing speed through lower FA in callosal and associative ﬁber
tracts. Longitudinal studies are needed to support this hypothesis.
Introduction
Numerous epidemiological studies showed that obesity, most often
measured using body mass index (BMI), is associated with accelerated
cognitive decline and an increased risk for dementia later in life (Fer-
genbaum et al., 2009; Fitzpatrick et al., 2009; Gustafson et al., 2009;
Whitmer et al., 2008), for reviews see (Albanese et al., 2017; Emmerzaal
et al., 2015; Prickett et al., 2015). However, this detrimental relationship
has been questioned: For example, Qizilbash et al. (2015) analysed
retrospectively online health-care data of over 2 million people in the UK
and reported that obese people had a lower dementia risk. Others
observed that obesity in midlife but not in old age exerts detrimental
effects on cognitive decline (Gustafson, 2015). These phenomena might
be explained by reverse causation due to weight loss at the preclinical
stage of dementia, a hypothesis supported recently by data including over
1.3 million participants from 39 prospective cohorts (Kivim€aki et al.,
2017). Clarifying the debate if obesity exerts negative effects on brain
health even in older age is crucial from a public health perspective.
Because in 2016, about 40% of adults worldwide were overweight, and
the prevalence rate of both obesity and Alzheimer's disease is rapidly
increasing (Alzheimer’s Association, 2016; WHO, 2016).
Cognitive decline has been linked to neuroimaging markers of grey
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matter atrophy (Karas et al., 2004) and regional white matter damage
(Bartzokis et al., 2004; Brickman et al., 2006; Lampe et al., 2017; Madden
et al., 2012; Vernooij et al., 2009). Obesity could cause white matter
damage due to multiple physiological factors, including high blood pres-
sure, low-grade inﬂammation, and insulin resistance (Pugazhenthi et al.,
2016; Shefer et al., 2013; Willette et al., 2015). Thus, obesity-associated
regional white matter damage might be one underlying mechanism of
cognitive differences in the general population, either independent of age
or as a trigger or booster of age-associated changes. This hypothesis,
however, has not yet been systematically explored.
Regarding obesity and global measures of white matter, available
neuroimaging studies yielded inconclusive results (Bobb et al., 2014;
Driscoll et al., 2012; Karlsson et al., 2013; Raji et al., 2010; Walther et al.,
2010). Using studies implementing sensitive diffusion tensor imaging
(DTI) to assess fractional anisotropy (FA), a measure of directional
diffusion of water molecules in the white matter (Alexander et al., 2007),
correlated obesity in healthy adults to lower FA with relative consistency
(Bettcher et al., 2013; Karlsson et al., 2013; Kullmann et al., 2016;
Mueller et al., 2011; Ryan and Walther, 2014; Stanek et al., 2011; Ver-
stynen et al., 2012). These obesity-associated differences were found in
diverse, not necessarily overlapping, brain regions and were partially
restricted to either men or women. For the ﬁrst time, a recent study re-
ported a positive relationship between obesity and FA (Birdsill et al.,
2017). Thus, it is still unclear if obesity is detrimental for white matter
microstructure, and if this effect is age-, sex- or region-speciﬁc. In addi-
tion, if obesity-associated white matter microstructural changes would
relate to cognitive changes remains unclear.
Previous conﬂicting ﬁndings might be explained by differences
among studies in methodology but also when considering speciﬁc aspects
of obesity and demographic confounders (Kullmann et al., 2015). For
example, several studies reported detrimental effects for visceral obesity
(often measured by waist-to-hip ratio, WHR), but overall obesity as
measured by BMI showed less or no effect on white matter microstructure
(Gustafson et al., 2009; Karlsson et al., 2013; Whitmer et al., 2008). In
addition, previous studies often neglected the possibility of residual
confounding, e.g., through risk factors related to obesity (hypertension,
Rahmouni, 2014; or diabetes, Van Gaal et al., 2006), white matter lesions
(Kim et al., 2017), and/or cognitive decline (e.g., education, Garibotto
et al., 2008) and common polymorphisms in the Apolipoprotein E
(APOE) ε4-gene (Ryan et al., 2011). This highlights the importance of a
well-characterized sample, tight control of confounders, and sensitive
cognitive testing.
We therefore aimed to determine if obesity is correlated with regional
white matter microstructure in a large cohort of otherwise healthy men
and women across the adult lifespan by evaluating linear and nonlinear
effects of both BMI and WHR, applying strict exclusion criteria, and
controlling possible confounders. In addition, we tested if associations
between obesity and regional white matter microstructure would trans-
late into inter-individual differences in main domains of cognitive per-
formance using structural equation path analyses (Hayes and Preacher,
2014), a method frequently used to explore mediating pathways between
age, metabolic factors, brain structure, and cognition (Kerti et al., 2013;
Mander et al., 2013; Ryan and Walther, 2014). We hypothesized that
obesity was associated with lower FA in both men and women and with
cognitive functions through lower FA in areas that are supportive of
executive control, memory, and processing speed in older individuals.
Materials and methods
Participants
The study participants were from the population-based “Leipzig
Research Center for Civilization Diseases” (LIFE-Adult) cohort in Leipzig,
Germany (Loefﬂer et al., 2015). A total of 2637 participants underwent
magnetic resonance imaging (MRI) of the head, among which 2523
participants completed a diffusion-weighted imaging (DWI) protocol.
One third of the DWI scans were rated as non-usable due to chemical shift
artifacts identiﬁed by visual inspection on raw diffusion-weighted and
diffusion tensor V1 images (for an example see supplement Fig. S1). Such
an artifact is caused by insufﬁcient fat suppression during image acqui-
sition, and incomplete fat suppression could still occur because it highly
depends on the suppression method and scanner-speciﬁc settings (Tax
et al., 2016). We excluded those scans because this artifact would bias
tensor estimation locally, and correction during preprocessing is difﬁcult
(Tax et al., 2016). Of 1713 usable DWI scans, we excluded participants
due to brain pathologies (n¼ 169), cancer treatment (n¼ 59), and intake
of medication that affects the central nervous system (n¼ 156) (Fig. 1).
We further excluded participants with missing values (n¼ 60) in all
cognitive tests or BMI. To exclude severe cognitive impairments, we
excluded participants with an average global cognitive sum-score (see
below) below 3 standard deviations of the subgroup mean (n¼ 6< 60y,
and n¼ 8 60–80y) (Masouleh et al., 2016), leaving 1255 participants for
main analysis.
Image acquisition and processing
Diffusion-weighted images were acquired on a 3-T MRI scanner
(Verio, Siemens, Germany) with a double spin-echo encoding sequence
which lasted 16min 8 s (repetition time [TR]¼ 13800ms; echo time
[TE]¼ 100ms; ﬁeld of view [FOV]¼ 220# 220# 123mm3; ma-
trix¼ 128# 128; voxel size¼ 1.7# 1.7# 1.7mm3; maximum b-
value¼ 1000 s/mm2 in 60 directions, and 7 volumes with b-value¼ 0 s/
mm2). Participants were scanned from 8am to 3pm on weekdays.
Following the ENGIMA (Enhancing Neuroimaging Genetics Through
Meta Analysis, www.enigma.ini.usc.edu)-DTI protocol, we used the
Diffusion Toolbox, which is part of FMRIB Software Library (FSL v5.0.9)
(Smith et al., 2004), to process diffusion images. Firstly, the raw data for
each participant were corrected for head motion and distortions by
registering them to the no diffusion-weighted (b¼ 0) image with an
afﬁne transformation. Subsequently, non-brain structures were removed
by the BET tool (Smith, 2002) with b¼ 0 image as reference. FA images
were then created by ﬁtting a tensor model to the raw diffusion data with
rotated bvec ﬁles. After that, tract-based spatial statistics (TBSS) were
used to carry out voxelwise statistical analysis (Smith et al., 2006).
Brieﬂy, all participants' FA images were ﬁrst registered to a FMRIB58_FA
standard-space image with a non-linear registration tool FNIRT (Ander-
sson et al., 2007a, 2007b). This step created a standard-space version of
each individual's FA image and merged all into a single 4D image. From
the 4D image, a mean FA image was generated and thinned to create a
mean FA skeleton. The skeleton was then used for projecting each sub-
ject's aligned FA data and creating the 4D skeletonized FA image for
voxelwise cross-subject statistics. The voxelwise analyses were carried
out for all voxels with FA ! 0.3 to exclude extreme cross-subject vari-
ability within small individual white matter tracts as well as incorrect
alignments in the registration.
Cognitive evaluation
We assessed cognitive performance using the neuropsychological test
battery of the Consortium to Establish a Registry for Alzheimer's Disease
(CERAD) (Morris et al., 1989). These tests comprised the Trail-Making
Test (TMT) parts A and B, Verbal Fluency Test ‘Animals’ and ‘S’ words,
and a 10-word list for the verbal episodic memory test. For the latter,
“learning” was deﬁned as the sum of correctly named words out of three
consecutive learning trials. “Recall” was deﬁned as the number of
correctly recalled words from the list after a delay, in which participants
performed a ﬁgure copy task (~5min), and “recognition” was deﬁned as
the sum of correctly recognized words from a list of 20 mixed words
presented after the recall trial. Three composite scores for the cognitive
domains of executive functions, memory performance, and processing
speed were deﬁned according to previous studies (Masouleh et al., 2016;
van de Rest et al., 2008; Witte et al., 2014) as: ‘executive functions’ ¼ [z
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Fig. 1. Flowchart of the study. From 1713
participants with usable diffusion-weighted
scans, n¼ 1255 entered whole-brain voxel-
wise analyses of obesity, namely body mass
index (BMI, n¼ 1255) and waist-to-hip
ratio (WHR, n¼ 1251), on white matter
microstructure. Subsequently, obesity and
regional white matter microstructural vari-
ability were related to cognitive perfor-
mance using correlations and mediation
analyses. Abbreviations: DWI, diffusion-
weighted imaging; SD, standard deviation;
TBSS, tract-based spatial statistics; FA,
fractional anisotropy; APOE, Apolipopro-
tein E.
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phonemic ﬂuency þ z semantic ﬂuency - z TMT(part B - part A)/part
A]/3; ‘memory performance’ ¼ (z learning þ z recall þ z recognition)/3;
‘processing speed’ ¼ -z TMT part A. See supplementary Fig. S2 for dis-
tribution of the composite scores and Table S1 for overview of the raw
cognitive subtest-scores. In addition, a global cognitive sum-score was
deﬁned as the average age-adjusted performance in executive functions,
memory performance and processing speed in a young group (<60 y) and
in an older group (60–80 y) (Masouleh et al., 2016).
Anthropometric assessments and confounder deﬁnition
BMI (kg/m2) was calculated as weight in kilograms divided by height
squared in meters, both measured on a standard scale to the nearest
0.01 kg or 0.1 cm. WHR was deﬁned as waist circumference divided by
hip circumference measured by an ergonomic circumference measuring
tape (SECA 201) to the nearest 0.1 cm. Education was evaluated based on
the International Standard Classiﬁcation of Education (Unesco, 1997),
and years of education were counted as years one had been at school
according to the respective graduation level (self-reported). Hyperten-
sion was deﬁned as a systolic blood pressure higher than 140mmHg or a
diastolic blood pressure higher than 90mmHg (Mancia et al., 2013), by
indirect assumption when they took antihypertensive medication, or by
clinical diagnosis. Diabetes mellitus was deﬁned by self-reported diag-
nosis and use of medication. APOE genotype was used dichotomously:
APOE-ε4 carrier versus non-carrier. Individual white matter hyper-
intensity volume (WMHV) was calculated with an automatic segmenta-
tion tool (LesionTOADS) (Lampe et al., 2017; Shiee et al., 2010) and
adjusted for global white matter volume.
Statistical analyses
Obesity and white matter
To test the association between obesity and white matter micro-
structure, we performed voxelwise cross-subject whole-brain analyses of
BMI and WHR, respectively, on FA skeletonized maps, adjusting for age,
sex, and WMHV. Nonparametric inference testing was conducted using
the “randomise” tool in FSL with 10,000 permutations (Winkler et al.,
2014). In addition, we tested for quadratic effects of obesity measures
and for interactions between obesity measures and age or sex. In adjusted
models we controlled for potential confounding effects of obesity-related
comorbidities (hypertension and diabetes), and APOE-ε4 status. Further
sensitivity analyses were done in males and females separately. Multiple
comparisons were corrected by threshold-free cluster enhancement
(Smith and Nichols, 2009) and family-wise error (FWE) at a signiﬁcance
level of p< 0.05. Effect sizes of these analyses were compared using a
one-sample t-test of the voxelwise differences in t-values.
Cognitive performance
Relations between BMI or WHR and cognitive composite scores were
examined with partial correlations. Signiﬁcance level was set at an
adjusted p-value¼ 0.017 for multiple comparisons< 0.05 (Bonferroni-
corrected p< 0.05, 3 domains tested, 2-sided). To examine the potential
role of regional BMI- andWHR-associated white matter variability on the
relation between BMI or WHR and cognitive performance (Ryan and
Walther, 2014; Scholz et al., 2009), we performed simple mediation
analyses controlled for age and sex. Therefore, we a-priori selected the
following major white matter tracts based on previous results linking
white matter microstructure with cognitive performance (Borghesani
et al., 2013; Gold et al., 2012; Madden et al., 2009a, 2009b; Ryan and
Walther, 2014; Salami et al., 2012): uncinate fasciculus, corpus callosum,
anterior thalamic radiation, superior and inferior longitudinal fasciculus,
and cingulum. These regions were masked on the white matter skeleton
with the JHU ICBM-DTI-81 atlas, and individual mean FA was extracted
in regional clusters that were signiﬁcantly associated with BMI according
to TBSS analyses (FWE-corrected p< 0.05) (see Fig. 2). Subsequently, we
analysed associations of mean FA in these BMI/WHR-associated clusters
with cognitive performance in the mediation analyses. The indirect effect
was considered signiﬁcant if zero was not included in the 99%
bias-corrected conﬁdence intervals (CI) based on 10,000 bootstrap
samples. We controlled for education, APOE-ε4 status, and comorbid-
ities, namely hypertension and diabetes, as confounders in a subsequent
model.
Missing values
Because of missing WHR measures in 4 subjects, 1251 participants
were included in the voxelwise cross-subject whole-brain analysis for the
association between WHR and FA. Missing values of WMHV were
replaced by the median WMHV value of the respective Fazekas’ scale
category (Fazekas et al., 1987), or, if the Fazekas rating was not available,
by the median of the respective age group (<60 y or 60–80y). Each
cognitive composite score was calculated based on the average of the
remaining available subtests when there were missing values in any of
the cognitive subtests (Masouleh et al., 2016). Participants missing one of
the composite scores were excluded in further analyses with pairwise
strategy.
A log transformation was performed if the absolute value of skewness
exceeded one. All analyses were conducted with psych and Hmisc
package in R (Harrell et al., 2016; R Core Team, 2016; Revelle, 2017)
except for the mediation analysis which was done by PROCESS SPSS
macro (Hayes and Preacher, 2014) in SPSS 24 (PASW, SPSS, IBM).
Results
We included 1255 non-demented participants in the main analysis;
see Table 1 for an overview of anthropometric characteristics.
Obesity and white matter microstructure
TBSS analysis detected a signiﬁcant association between higher BMI
and lower FA in multiple, mainly bilateral regions of the cerebral white
matter tracts (Fig. 3, p< 0.05, FWE-corrected, controlled for age, sex, and
WMHV). Results remained stable when correcting additionally for con-
founding effects of diabetes, hypertension, and APOE-ε4 carrier status
(Fig. S3). The affected white matter tracts included the entire corpus
callosum, cerebral peduncle, internal capsule, corona radiata, superior
and inferior longitudinal fasciculus, anterior and posterior thalamic ra-
diation, external capsule, superior cerebellar peduncle, and uncinate
fasciculus.
Considering WHR as a predictor, we detected an overall very slightly
larger effect (voxel-wise comparison, Cohen's d WHR>BMI¼ 0.08,
Fig. 2. Regions of interest on the white matter
skeleton: corpus callosum genu (CC-G), body
(CC-B) and splenium (CC-S), inferior and supe-
rior longitudinal fasciculus (ILF and SLF),
cingulum (CG), uncinate fasciculus (UNC) and
anterior corona radiata (ACR).
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p< 10%4) which was a signiﬁcant association between higher WHR and
lower FA on multiple white matter tracts almost throughout the whole
white matter skeleton in the frontal, temporal, and parietal lobes (Fig. 4,
p< 0.05, FWE-corrected, controlled for age, sex, and WMHV). Results
remained stable when correcting additionally for confounding effects of
diabetes, hypertension, and APOE-ε4 carrier status (Fig. S4).
There were neither quadratic effects nor main interaction effects of
BMI or WHR by age or sex in this large dataset after appropriate
correction (FWE-corrected, p> 0.05). However, sensitivity analyses for
sex groups separately indicated that the association was slightly stronger
in female (BMI: voxel-wise comparison, Cohen's d female>male¼ 0.05,
p< 10%4, Fig. 5; WHR: voxel-wise comparison, Cohen's d fema-
le>male¼ 0.34, p< 10%4).
We did not observe signiﬁcant positive associations between BMI or
WHR and FA.
As head motion can affect data quality and was found to be correlated
with BMI (Beyer et al., 2017; Hodgson et al., 2017), we additionally
controlled for head motion, measured by mean framewise displacement
(FD) derived by rigid-body co-registration during preprocessing (Power
et al., 2012). This did not attenuate the results (Fig. S5–6). In addition,
excluding participants with mean FD> 1mm gave similar results (data
not shown).
Cognitive performance analyses
We found a signiﬁcant negative correlation between WHR and
memory performance (r¼%0.09, p¼ 0.005, controlled for age and sex),
however the effect diminished after further adjustments, namely edu-
cation, diabetes, hypertension, and APOE-ε4 (Table 2). There were no
signiﬁcant correlations between BMI and cognition after adjusting for
confounders (all p> 0.03, Table 2).
Mediation analyses
While the direct link between obesity and cognitive performance
appeared to be limited, simple mediation analyses indicated speciﬁc
causal pathways between obesity, regional white matter microstructure,
and cognitive function. That is, higher BMI and higher WHR contributed
to poorer performance in executive functions and processing speed
through lower FA in clusters within the superior and inferior lateral
fasciculus, left anterior thalamic radiation, and in the body of the corpus
callosum (99% jCIj> 0, Figs. 6 and 7, Tables 3 and 4). Associations
remained stable for WHR-related effects after adjusting for all con-
founders in the corpus callosum, left arcuate thalamic radiation, and left
superior longitudinal fasciculus. We did not observe robust associations
for further mediating pathways.
Discussion
In this large cross-sectional study of 1255 older individuals, we found
independent associations between obesity and lower FA in multiple
white matter tracts comprising the corpus callosum, superior and inferior
longitudinal fasciculus, corona radiata, thalamic radiation, uncinate
fasciculus, cingulum, and brainstem. While the direct link between
obesity and cognition in this cohort was limited, mediation analyses
supported the existence of detrimental pathways linking obesity to worse
executive functions and lower processing speed through lower FA in
callosal and associative ﬁber tracts.
Obesity and white matter
Our ﬁnding of an inverse association between obesity and white
matter FA extends previous small studies (all n< 60) in young and
middle-aged participants that reported negative correlations in fewwhite
matter areas (Karlsson et al., 2013;Mueller et al., 2011; Shott et al., 2015;
Verstynen et al., 2013; Xu et al., 2013; Yau et al., 2014), for a review see
(Kullmann et al., 2015). Two recent studies conducted in medium-sized
Fig. 3. Association of higher body mass index (BMI) and lower white matter fractional anisotropy (FA) adjusted for age, sex, and volume of white matter
hyperintensities (p< 0.05, family-wise-error-corrected, n¼ 1225). This ﬁgure is layered on a T1-weighted image (coordinates according to MNI152 template).
Color bar represents t-value. Abbreviations: L, left; R, right.
Table 1
Characteristics of included study participants (n¼ 1255).
Characteristic Descriptives
Sex (female), n (%) 636 (50.7)
Age, mean (SD), range, y 55.43 (16.05), 19–80
BMI, mean (SD), range, kg/m2 25.82 (3.69), 16.81–50.15
WHRa, mean (SD), range 0.91 (0.09), 0.64–1.17
Years of Educationb, mean (SD), range, y 10.7 (2.1), 0–13
APOE-ε4 carrierc, n (%) 276 (23.5)
Hypertension, n (%) 701 (55.9)
Diabetesd, n(%) 97 (8.3)
Executive functione, mean (SD), range 0.01 (0.72), %3.27–3.03
Processing speed (log10)f, mean (SD), range 0.47 (0.13), 0–0.88
Memory performance (log10)g, mean (SD), range 0.51 (0.13), 0–0.83
Abbreviations: SD, standard deviation; BMI, body mass index; WHR, waist-to-hip ratio;
APOE, Apolipoprotein E.
a n¼ 1251.
b n¼ 1188.
c n¼ 1175.
d n¼ 1165.
e n¼ 1193.
f n¼ 1188.
g n¼ 1206.
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samples (n¼ 103, lifespan sample, Stanek et al., 2011; n¼ 238,
middle-aged hypertensive patients, Papageorgiou et al., 2017) extended
results that obese and/or overweight participants had partially lower FA
compared to their lean counterparts in the corpus callosum, thalamic
radiation, uncinate fasciculus, and inferior and superior longitudinal
fasciculus. This is in line with the current ﬁndings, yet without showing
such a widespread pattern of regions associated with continuous
increases in BMI and WHR. The affected regions observed in our sample
were also partially reported when examining obesity-associated white
matter microstructure speciﬁcally in older groups with sample sizes be-
tween 15 and 138 subjects (Bettcher et al., 2013; Bolzenius et al., 2015;
Marks et al., 2010; Ryan andWalther, 2014), yet again showing a smaller
regional correlations between BMI and FA. Besides the smaller sample
sizes and related lower statistical power, this could also be due to
Fig. 4. Association of higher waist-to-hip ratio (WHR) and lower white matter fractional anisotropy (FA) adjusted for age, sex, and volume of white matter
hyperintensities (p< 0.05, family-wise-error-corrected, n¼ 1251). This ﬁgure is layered on a T1-weighted image (coordinates according to MNI152 template).
Color bar represents t-value. Abbreviations: L, left; R, right.
Fig. 5. Inverse correlation between body mass index (BMI) and fractional anisotropy (FA) in the white matter between sex groups. First row is the correlation in
men and the second row is the correlation in women, showing lower FA associated with higher BMI adjusted for age and volume of white matter hyperintensities
(p< 0.05, family-wise-error-corrected). This ﬁgure is layered on a T1-weighted image (coordinates according to MNI152 template). Color bar represents t-value.
Abbreviations: L, left; R, right.
Table 2
Correlations between BMI or WHR and cognitive performance.
Executive function Memory performance Processing speed
n r (95%CI) p n r (95%CI) p n r (95%CI) p
Model 1a
BMI 1193 %0.06 (%0.12, %0.007) 0.03 1206 %0.04 (%0.09, 0.02) 0.19 1188 0.02 (%0.04, 0.08) 0.51
WHR 1189 %0.06 (%0.12, %0.004) 0.03 1202 ¡0.09 (¡0.14, ¡0.03) 0.005* 1184 >0.9
Model 2b
BMI 1089 >0.9 1048 %0.006 (%0.07, 0.05) 0.85 1086 0.009 (%0.05, 0.07) 0.76
WHR 1085 %0.03 (%0.09, 0.03) 0.26 1044 %0.07 (%0.13, %0.008) 0.026 1082 %0.02 (%0.07, 0.04) 0.6
Abbreviations: BMI, body mass index; WHR, waist-to-hip ratio.
Adjusted p¼ 0.017.
a Controlled age and sex as confounders.
b Model 1 added education, APOE-ε4 status and comorbidities (diabetes, hypertension) as confounders.
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methodological limitations, for example, atlas-based region-of-interest
approach to delineate white matter differences in these studies,
compared to the more sensitive whole-brain voxel-wise TBSS analysis in
our study.
Our results further indicate a slightly stronger effect of WHR
compared to BMI. As WHR is an indicator of higher abdominal fat and
better reﬂects visceral fat than BMI (Shuster et al., 2012), this could
imply that abdominal fat deposition, in particular visceral fat, is more
detrimental to white matter FA variability than overall fat or body
weight. When measuring body composition using e.g., bioelectrical
impedance analysis, women have signiﬁcantly higher fat percentages
thanmen, even at the same BMI (Gallagher et al., 1996; Kyle et al., 2003).
In addition, previous studies suggested sex-speciﬁc effects of obesity on
FA (Mueller et al., 2011). This could be due to known anatomical dif-
ferences or hormonal effects (Liu et al., 2010; Menzler et al., 2011; Peper
et al., 2011). Exploratory comparisons of whole-brain results from ana-
lyses separately in males and females in our study gave hints for a
somewhat stronger association in female compared to male, speciﬁcally
for WHR. One explanation for these observations might be a stronger
collinearity of WHR with age in males explaining twice as much of the
variance compared to females (age~WHR R2 males¼ 0.41, R2 fe-
males¼ 0.19): This might have led to a certain overﬁtting in the male
group. In addition, an interaction of obesity measures on FA by sex did
not show signiﬁcant effects in the pooled analysis. Thus, our results do
not provide strong evidence for the existence of sex differences in the
effects of obesity on FA. Future studies incorporating direct measure-
ments of body composition could help to further understand differences
between BMI, WHR, and the role of visceral fat on FA, as well as potential
differences in men and women.
Contrary to our hypotheses, we could not observe nonlinear trends for
obesity effects, i.e., a quadratic term of BMI or WHR would indepen-
dently explain more variance in the data than BMI or WHR as a linear
term. In addition, there was no signiﬁcant age-by-BMI or age-by-WHR
interaction when additionally controlling for linear effects of age and
BMI/WHR. This implies that effects of obesity across the lifespan are
rather linear. However, the recruitment of participants for the LIFE-study
was intended to focus on participants over 60 years of age (please see
Loefﬂer et al., 2015, for details) and our mean age was 55.43
years& 16.05 SD, which might have led to a certain underrepresentation
of young adults in our cohort. In addition, due to existing collinearities
between higher age and higher BMI/WHR, we cannot completely
exclude nonlinear effects of obesity over the lifespan.
Obesity and cognitive performance
In our cohort, correlations between obesity and cognition appeared to
be weak or non-signiﬁcant when adjusted for possible confounding ef-
fects of age, sex and education. This might be insightful given that effect
sizes for unique effects of obesity on cognitive decline were estimated to
be rather small (Livingston et al., 2017). In addition, our cohort
comprised of cognitively healthy adults, combining relatively strict
exclusion criteria with a wide age range that could already account for a
Fig. 6. Clusters from body mass index (BMI)-associated white matter tracts
extracted within the left inferior longitudinal fasciculus (ILF) and within the
right superior longitudinal fasciculus (SLF) (threshold-free cluster enhance-
ment and family-wise error corrected p< 0.05).
Fig. 7. Clusters from waist-to-hip-ratio
(WHR)-associated white matter tracts
extracted within the corpus callosum body
(CC-B), right inferior longitudinal fasciculus
(ILF), left anterior corona radiata (ACR) and
superior longitudinal fasciculus (SLF)
(threshold-free cluster enhancement and
family-wise error corrected p< 0.05).
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large amount of variability in cognitive performance.
While our cross-sectional dataset is unable to prove causality, medi-
ation analyses provided initial evidence based on a large amount of ob-
servations for the existence of a detrimental pathway between obesity,
white matter microstructure, and cognitive performance. Accordingly,
mediation analyses indicated that obesity contributed to poorer execu-
tive functions and lower processing speed through lower FA in obesity-
associated regions of the white matter skeleton, independent of age
and sex. Those were located within major tracts which have previously
been linked to higher-order cognitive abilities, including the corpus
callosum, the anterior thalamic radiation, and the superior and inferior
longitudinal fasciculus (Boorman et al., 2009; Borghesani et al., 2013;
Jacobs et al., 2013; Kennedy and Raz, 2009; Kochunov et al., 2009;
Salthouse, 2011; partly even independent of age; Brickman et al., 2006;
Jokinen et al., 2007). Associations in the corpus callosum, left anterior
thalamic radiation, and left superior longitudinal fasciculus with the
visceral obesity marker WHR remained stable even after controlling for
education, diabetes, and hypertension, as well as genetic factors under-
scoring the robustness of these effects. We conﬁrmed and further
extended previous results of 95 older females, showing mediating effects
Table 3
Mediation effect of regional FA on the association between BMI and cognitive function.
SLF R
executive functions
SLF R
processing speed
ILF L
processing speed
β p or 99.5% CI β p or 99.5% CI β p or 99.5% CI
Model 1a
Total effect c (BMI on cognition) %0.06 0.028 0.02 0.5 0.02 0.5
a (BMI on FA) %0.08 0.008 %0.08 0.007 %0.08 0.007
b (FA on cognition) 0.13 <0.001 0.07 0.008 0.07 0.006
Mediation effect a*b (BMI on cognition via FA) ¡0.01 [¡0.025, ¡0.0005] ¡0.005 [¡0.025, ¡0.0001] ¡0.005 [¡0.017, ¡0.0001]
Direct effect c’ (BMI on cognition) %0.06 0.06 0.02 0.38 0.02 0.38
Abbreviations: BMI, body mass index; FA, fractional anisotropy, SLF, superior longitudinal fasciculus, ILF, inferior longitudinal fasciculus, R, right, L, left.
a Controlled age and sex as confounders.
Table 4
Mediation effect of regional FA on the association between WHR and cognitive function.
CC body
executive functions
SLF R
executive functions
SLF R processing
speed
SLF L
executive functions
SLF L processing
speed
β p or 99.5% CI β p or 99% CI β p or 99% CI β p or 99% CI β p or 99% CI
Model 1a
Total effect c (WHR on
cognition)
%0.09 0.035 %0.09 0.035 %0.005 0.8 %0.09 0.035 %0.005 0.89
a (WHR on FA) %0.13 <0.001 %0.11 0.004 %0.12 0.003 %0.12 0.002 %0.13 0.002
b (FA on cognition) 0.08 0.015 0.13 <0.001 0.08 0.002 0.10 0.001 0.09 <0.001
Mediation effect a*b (WHR
on cognition via FA)
¡0.01 [¡0.026,
¡0.0008]
¡0.02 [¡0.037,
¡0.0023]
¡0.01 [¡0.025,
¡0.001]
¡0.01 [¡0.032,
¡0.002]
¡0.01 [¡0.027,
¡0.002]
Direct effect c’ (WHR on
cognition)
%0.08 0.061 %0.08 0.08 0.01 0.8 %0.08 0.069 %0.006 0.86
Model 2b
Total effect c (WHR on
cognition)
%0.05 0.26 %0.02 0.6 %0.05 0.26 %0.02 0.59
a (WHR on FA) %0.11 0.008 %0.11 0.012 %0.11 0.009 %0.11 0.008
b (FA on cognition) 0.08 0.014 0.09 <0.0001 0.09 0.002 0.09 <0.001
Mediation effect a*b (WHR
on cognition via FA)
¡0.009 [¡0.025,
¡0.0002]
n.s. ¡0.01 [¡0.026,
¡0.0005]
¡0.01 [¡0.031,
¡0.0003]
¡0.01 [¡0.027,
¡0.0009]
Direct effect c’ (WHR on
cognition)
%0.04 0.36 %0.01 0.8 %0.04 0.38 %0.009 0.80
ACR L
executive functions
ACR L
processing speed
ILF R
executive functions
ILF R
processing speed
β p or 99.5% CI β p or 99% CI β p or 99% CI β p or 99% CI
Model 1a
Total effect c (WHR on cognition) %0.09 0.035 %0.001 0.9 %0.09 0.035 %0.005 0.9
a (WHR on FA) %0.12 <0.001 %0.12 <0.001 %0.10 0.014 %0.11 0.008
b (FA on cognition) 0.09 0.015 0.09 0.003 0.10 0.001 0.08 0.002
Mediation effect a*b (WHR on cognition
via FA)
¡0.01 [¡0.027,
¡0.0001]
¡0.01 [¡0.027,
¡0.002]
¡0.01 [¡0.029,
¡0.0003]
¡0.01 [¡0.024,
¡0.0008]
Direct effect c’ (WHR on cognition) %0.08 0.062 0.01 0.8 %0.08 0.06 0.004 0.9
Model 2b
Total effect c (WHR on cognition) %0.05 0.26 %0.02 0.6
a (WHR on FA) %0.09 0.014 %0.09 0.014
b (FA on cognition) 0.10 0.006 0.11 <0.001
Mediation effect a*b (WHR on cognition
via FA)
¡0.009 [¡0.026,
¡0.0002]
¡0.01 [¡0.027,
¡0.0006]
n.s. n.s.
Direct effect c’ (WHR on cognition) %0.04 0.36 %0.01 0.8
Abbreviations: WHR, waist-hip ratio; FA, fractional anisotropy; CC, corpus callosum; SLF, superior longitudinal fasciculus; ACR, anterior thalamic radiation; ILF, inferior longitudinal
fasciculus; R, right; L, left.
a Controlled age and sex as confounders.
b Model 1 added education, APOE-ε4 status and comorbidities (diabetes, hypertension) as confounders.
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of obesity on cognition through white matter FA (Ryan and Walther,
2014). In the latter study, diffusion measures in mostly temporal and
parietal white matter also predicted memory performance (Ryan and
Walther, 2014), a result that was not conﬁrmed by our data. However
note that the fornix region as a major tract of the limbic system impli-
cated in memory processes did not show associations with BMI or WHR
at the chosen signiﬁcance level and was therefore not considered in the
cognitive mediation analyses.
Regarding the underlying mechanisms, FA has been discussed as a
measure for white matter microstructure due to its high sensitivity to
neuropathology and microstructural architecture (Alexander et al.,
2007). Thus, lower FA in white matter tracts might indicate dysfunc-
tional properties of connecting axonal ﬁbers, thereby provoking disad-
vantages in cognitive processing (Johansen-Berg and Behrens, 2006).
Obesity-associated changes in white matter FA might be due to
low-grade inﬂammation, a condition frequently related to obesity. For
example, in healthy populations, increased inﬂammatory markers such
as interleukin-6 and C-reactive protein have been associated with
reduced white matter FA (Gianaros et al., 2013; Shott et al., 2015).
Consistently, diffusion measures in overweight and obese individuals
were predicted by plasma ﬁbrinogen levels, a marker of inﬂammation
(Cazettes et al., 2011). These cytokines are produced by adipose tissue (in
particular by visceral fat; Fontana et al., 2007; Johnson et al., 2012) and
can enter the central nervous system as a result of a disrupted blood–-
brain barrier, possibly due to maintaining an energy dense Western diet
when being obese (Hargrave et al., 2016; Johnson et al., 2012; Pugaz-
henthi et al., 2016). Future longitudinal studies investigating the role of
obesity-associated inﬂammation in provoking white matter damage and
related cognitive decline are needed to further strengthen these
hypotheses.
Limitations
Our study has some limitations. First, due to the cross-sessional
design, no causal relationships can be established based on our results.
However, path analyses indicated mediating links between obesity,
white matter FA, and cognitive performance. Regarding the memory
performance, the CERAD-recognition memory subtest showed some
ceiling effects in our cohort, which might have affected statistical power.
Limitations shared by all DTI and voxel-based studies include potential
registration errors and spatial smoothing. However, we increased the
mean FA skeleton threshold to 0.3 to exclude tracts that were not well
aligned across subjects (Smith et al., 2006). Another limitation of our
study is that we did not evaluate axial and radial diffusivity (AD and RD),
further DTI measures which might give additional insights into white
matter microstructure (Alexander et al., 2007). Strengths of the study
include the large sample size of community-dwelling adults with exten-
sive data on demographic, cognitive assessments, and potential con-
founding factors. Although evaluation of education was somewhat
skewed to higher education, our cohort showed the full range from 0 to
13 years of education. Note that participants were randomly invited from
the Leipzig city registry, thus the study sample should well represent the
general population of Eastern Germany. In addition, participants un-
derwent high resolution DWI at 3T with 60 directions which guaranteed
robust estimates of tensor-derived properties (Jones et al., 2013).
Conclusions
We found that obesity in adults is associated with lower FA in mul-
tiple white matter tracts throughout the brain. Moreover, although effect
sizes were small, mediation results indicated that visceral obesity was
linked to poorer executive functions and lower processing speed through
lower FA in callosal and associative ﬁber tracts. Thus, our ﬁndings might
help to assess the complex interplay between obesity and subtle cognitive
impairments, and point to the need for curative options. Upcoming
longitudinal studies on obesity, white matter changes, and cognition are
warranted to conﬁrm our hypotheses and to identify factors that help to
prevent or reverse the development of obesity and obesity-associated
brain damage.
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A B S T R A C T
Introduction: The polyphenol resveratrol has been suggested to exert beneﬁcial effects on memory and the aging
hippocampus due to calorie-restriction mimicking effects. However, the evidence based on human interventional
studies is scarce. We therefore aimed to determine the effects of resveratrol on memory performance, and to
identify potential underlying mechanisms using a broad array of blood-based biomarkers as well as hippocampus
connectivity and microstructure assessed with ultra-high ﬁeld magnetic resonance imaging (UHF-MRI).
Methods: In this double-blind, randomized controlled trial, 60 elderly participants (60–79 years) with a wide
body-mass index (BMI) range of 21–37 kg/m2 were randomized to receive either resveratrol (200mg/day) or
placebo for 26 weeks (registered at ClinicalTrials.gov: NCT02621554). Baseline and follow-up assessments
included the California Verbal Learning Task (CVLT, main outcome), the ModBent task, anthropometry, markers
of glucose and lipid metabolism, inﬂammation and neurotrophins derived from fasting blood, multimodal neu-
roimaging at 3 and 7 T, and questionnaires to assess confounding factors.
Results: Multivariate repeated-measures ANOVA did not detect signiﬁcant time by group effects for CVLT per-
formance. There was a trend for preserved pattern recognition memory after resveratrol, while performance
decreased in the placebo group (n.s., p¼ 0.07). Further exploratory analyses showed increases in both groups over
time in body fat, cholesterol, fasting glucose, interleukin 6, high sensitive C-reactive protein, tumor necrosis factor
alpha and in mean diffusivity of the subiculum and presubiculum, as well as decreases in physical activity, brain-
derived neurotrophic factor and insulin-like growth factor 1 at follow-up, which were partly more pronounced
after resveratrol.
Discussion: This interventional study failed to show signiﬁcant improvements in verbal memory after 6 months of
resveratrol in healthy elderly with a wide BMI range. A non-signiﬁcant trend emerged for positive effects on
pattern recognition memory, while possible confounding effects of unfavorable changes in lifestyle behavior,
neurotrophins and inﬂammatory markers occurred. Our ﬁndings also indicate the feasibility to detect (un)healthy
aging-related changes in measures of hippocampus microstructure after 6 months using 7T diffusion MRI. More
studies incorporating a longer duration and larger sample size are needed to determine if resveratrol enhances
memory performance in healthy older adults.
☆ General Theme: Cognition and Aging.
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Introduction
Food-derived polyphenols, common in the Mediterranean diet, have
been suggested to exert beneﬁcial effects on brain health (reviewed e.g.
in Davinelli et al., 2012; Bastianetto et al., 2015; Huhn et al., 2015). One
of the most extensively studied polyphenols is resveratrol, which occurs
in various natural sources such as blueberries, peanuts, red grapes and
red wine (Baur et al., 2006; Baur, 2010). In vitro as well as in vivo rodent
and primate studies provided evidence for antioxidative,
anti-inﬂammatory and calorie-restriction mimicking characteristics of
resveratrol (Baur, 2010; Bastianetto et al., 2015; Kulkarni and Canto,
2015). These effects have been discussed to contribute to improvements
in glucose-metabolism and cardiovascular factors (reviewed in Liu et al.,
2014; Kakoti et al., 2015; Huang et al., 2016), and eventually to pre-
served brain structure and neuronal function (discussed in Davinelli
et al., 2012; Huhn et al., 2015; Tellone et al., 2015; Wong and Howe,
2018).
While preclinical studies yielded exciting results, data from inter-
ventional human studies on the effect of polyphenols on brain structure
and cognition is scarce. Using small- to moderate sample sizes, few
randomized controlled trials (RCTs) in older adults reported improved
memory performance after supplementary intake of berry juice or for-
mulas with cocoa-ﬂavonol or other polyphenol-containing ingredients
(Krikorian et al., 2010; Brickman et al., 2014; Small et al., 2014). A
memory-enhancing effect in older adults has also been reported in two
RCTs for the intake of isolated resveratrol (150–200mg/day for 3 or 6
months) (Witte et al., 2014; Evans et al., 2017). In contrast, studies in
younger age or patient groups did not detect signiﬁcant effects of
resveratrol on cognitive functions (Turner et al., 2015; Wightman et al.,
2015; Zortea et al., 2016; Kobe et al., 2017). Also, a recent meta-analysis
(Farzaei et al., 2017) including 255 participants of four studies (Witte
et al., 2014; Wightman et al., 2015; Evans et al., 2017; Kobe et al., 2017)
concluded that resveratrol has no signiﬁcant impact on cognitive
performance.
Only few human studies so far included measures that could yield
underlying mechanistic insights. Two studies led by Kennedy and col-
leagues suggested that acute doses of 250mg or 500mg resveratrol
enhance cerebral blood ﬂow (Kennedy et al., 2010; Wightman et al.,
2015). Studies with a longer duration of resveratrol supplementation
(3–6 months) reported improvements in cerebrovascular responsiveness
to hypercapnia (Evans et al., 2017) and changes in magnetic resonance
imaging (MRI)-based measures of functional connectivity (FC) of the
hippocampus, a key region involved in memory processes (Witte et al.,
2014; Kobe et al., 2017). Witte et al. (2014) could also observe decreased
levels of glycated hemoglobin (HbA1c), a long-term marker of glucose
control, after resveratrol supplementation, which in turn correlated with
resveratrol-induced improvements in functional connectivity and verbal
memory. However, the hypothesis that resveratrol enhances human
memory performance via improvements or maintenance of hippocampus
functioning in aging remains to be established, and potentially related
mechanistic pathways are still debated (Huhn et al., 2015; Dias et al.,
2016; Figueira et al., 2017). Notably, so far only few longitudinal studies
in healthy elderly were able to show plastic changes in either regional
hippocampus blood volume (Pereira et al., 2007; Brickman et al., 2014)
or functional connectivity and volume (Erickson et al., 2011; Witte et al.,
2014) that followed a dose-response relationship with memory im-
provements after plasticity-enhancing interventions such as physical
exercise or polyphenol diets. Similarly, in longitudinal studies, systemic
changes such as improvements in physical activity or glucose metabolism
have only occasionally been linked to selective changes in the hippo-
campus (Erickson et al., 2011; Cherbuin et al., 2012; Maass et al., 2015;
Prehn et al., 2016).
This might be explained in part by the regional complexity of the
hippocampus and its sub-structures that have distinct morphological and
functional properties, as indicated by preclinical and post-mortem
studies (Mueller et al., 2011; Robinson et al., 2016). Using ultra-high
ﬁeld (UHF) MRI, though, it is now possible to delineate hippocampus
subﬁelds in vivo with higher signal-to-noise ratio and higher spatial res-
olution. This also enables to identify plastic changes at the subﬁeld level
more reliably (Iglesias et al., 2016; Giuliano et al., 2017). Implementing
7 Tesla (7T) UHF MRI in interventional studies would thus help to better
understand if and how the hippocampus translates potential
plasticity-enhancing effects of a systemic factor, such as diet, into speciﬁc
improvements in cognition (in this case memory). Therefore, we aimed
to examine the effects of resveratrol on memory performance in an in-
dependent sample of older adults by employing sensitive memory tests,
state-of-the-art 7T UHF MRI, and a broad array of blood-based bio-
markers. We hypothesized that 6 months of resveratrol supplementation
leads to improvements in memory performance, assessed with the Cali-
fornia Verbal Learning Task (CVLT; Niemann et al., 2008). Secondary
hypotheses included an improvement in glucose metabolism, reﬂected in
lower HbA1c levels after resveratrol supplementation, and improvements
in pattern recognition memory (Brickman et al., 2014). In addition, we
hypothesized resveratrol-induced improvements in functional connec-
tivity of the hippocampus within the default-mode network, and in
measures of regional hippocampus volume and microstructure, assessed
using 7T UHF MRI.
Material and methods
Participants and study design
Sixty healthy elderly participants (60–78 years) were recruited via the
Max Planck Institute’s database and local advertisements in Leipzig,
Germany. The research protocolwas approved by the Ethics Committee of
the University of Leipzig and was conducted in accordance with the
Declaration of Helsinki. All subjects gave written informed consent and
received reimbursement for participation. The trial was registered and a
study protocol was uploaded at ClinicalTrials.gov with the identiﬁer
NCT02621554. Baseline assessments were acquired from April to July
2016 and follow-up fromOctober 2016 to January2017 at theMaxPlanck
Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Potential participants were ﬁrst interviewed via telephone to screen
for eligibility criteria, i.e. over 60 years of age, body-mass index (BMI)
between 22 kg/m2 and 40 kg/m2. Exclusion criteria were MRI
Abbreviations:
ASAT/ALAT Alanine/Aspartate Aminotransferase
ApoE Apolipoprotein E
BDI Beck's Depression Inventory
BMI Body Mass Index
CV Coefﬁcient of Variation
CVLT California Verbal Learning Task
FC Functional Connectivity
FWE Family-Wise Error
HbA1c Glycated hemoglobin
HDL/LDL High/Low Density Lipoprotein
MNI Montreal Neurological Institute
MRI Magnetic Resonance Imaging
MD Mean Diffusivity
MMST Mini Mental Status Test
RCT Randomized Controlled Trial
SCD Subjective Cognitive Decline
TFCE Threshold-free Cluster Enhanced
TMT Trail Making Task
UHF Ultra-High Field
WHR Waist Hip Ratio
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contraindications (e.g. metal implants, pacemaker, tattoos), history of
stroke, current psychiatric disease, pregnancy, diabetes mellitus type 2 or
other severe internal diseases (e.g. affecting the gastro-intestinal tract,
lungs, heart, vascular system, liver or kidney), intake of antidepressants
or antioxidative supplements, daily consumption of more than 50 g
alcohol, 6 cups of coffee or 10 cigarettes (see Figure 2, all based on self-
reported information).
At baseline visits, participants completed a medical interview
including disease and medication anamnesis. To exclude subjects with
objective cognitive impairments, a cut-off level for performance in the
Mini Mental State Examination (MMSE; Folstein et al., 1975) of < 26 out
of 30 possible points was employed.
Participants were instructed to keep their diet and amount of physical
activity throughout the study duration unchanged.
Sample size determination and attrition
The number of subjects needed for this trial was determined with a
power calculation (Faul et al., 2007; Faul et al., 2009). The primary
outcome measure was a change in four subscales of the California Verbal
Learning Task after 6 months resveratrol supplementation. Based on
previous studies (Witte et al., 2009; Witte et al., 2013; Witte et al., 2014)
an effect-size (d) of 0.4 was assumed. With a signiﬁcance level
α¼ 0.05/4¼ 0.0125 (Bonferroni-corrected for multiple comparisons)
and a power of 95%, power analysis revealed a required sample size of 44
subjects. Assuming a drop out rate of 30% we aimed to recruit 60
participants.
During recruitment 193 participants were contacted. Of those, 66 did
not meet inclusion criteria (29 with diabetes, other diseases or centrally
active medication, 28 not MRI-suitable, 9 out of BMI range), 61 were not
interested in participating in the study and another six were not included
without further speciﬁed reasons (Figure 1). Thus, 60 subjects were
included into the study and randomly assigned to either intervention
group (n¼ 30) or placebo (n¼ 30) by a researcher who was not involved
in data acquisition. The intervention/placebo period was designed as a
parallel-group and double blind trial with 60 subjects with balanced (1:1)
randomization to either placebo or resveratrol group, stratiﬁed for age
(60–70 or > 70 years) and sex with a block size of four. A web-based
randomization system (www.randomization.com) was used. The last
participant was assigned in a way to get balanced groups with 30 subjects
irrespective of the randomization. After baseline-assessments and
randomization two participants of the placebo group were excluded due
to medication matching exclusion criteria. Another ﬁve participants
dropped out during the intervention period and were unavailable for
follow-up measurements. The dropout reasons in the resveratrol group
were a sudden decrease in eyesight (n¼ 1; after 18 weeks of pill intake),
a skin rash (n¼ 1; after 5 weeks of pill intake) and without further
speciﬁcation (n¼ 1). The two dropouts in the placebo group were due to
personal reasons (n¼ 1) and lost contact (n¼ 1). Other reported adverse
events that did not lead to exclusion or dropouts included stomach aches
(n¼ 1/1; resveratrol/placebo), diarrhea (n¼ 3/1), dizziness (n¼ 1/3),
vomiting (n¼ 0/1), skin changes (n¼ 3/3), mood changes (improve-
ments n¼ 1/1; decline n¼ 0/3), hot ﬂashes (n¼ 0/1), loss of hair (n¼ 1/
0), reﬂux (n¼ 0/1), rotating vertigo (n¼ 0/1), tight feeling in the chest
(n¼ 0/2), blood pressure ﬂuctuations (n¼ 0/1).
Intervention and compliance
Subjects were instructed to take two pills per day (one in the morning
and one in the afternoon) over 26 weeks. Resveratrol pills per day con-
tained 2" 100mg¼ 200mg resveratrol (3,5,40-trihydroxy-trans-stil-
bene) and 2" 160mg¼ 320mg quercetin to increase bioavailability
(Smoliga and Blanchard, 2014) in line with (Witte et al., 2014). Placebo
pills were identical in color and shape, but contained exclusively the
ﬁlling material (microcrystalline cellulose). Resveratrol was produced
using a yeast fermentation process and all pills were manufactured by
Evolva SA (Basel, Switzerland) and provided at no costs. Sponsoring
occurred without any terms or research assignments. At baseline par-
ticipants received a pill supply for 18 weeks and another pill supply at an
interim visit. At interim and follow-up visits, pill count and anamnis of
adverse events took place. Subjects and investigators were blinded for the
duration of the study to the treatment group. To estimate compliance,
remaining capsules at interim and follow-up visits were counted and
participants were asked to keep a pill diary. After follow-up, diaries and
pill counts of 41 participants were available. Additional 12 diaries/pill
counts were available for interim visits.
Outcome measures
For all participants at baseline and follow-up visits, we assessed
neuropsychological tests, blood parameters, anthropometric measures,
and neuroimaging (see Figure 2). All measures were executed according
to pre-speciﬁed protocols by trained staff. Cognitive testing was per-
formed on assessment day 2 before the 7T MRI scanning procedure. Due
to limited scanning slots assessment time was at baseline between 8 a.m.
and 4 p.m. and at follow up between 9 a.m. and 4 p.m.
Neuropsychological testing
We assessed verbal memory performance, i.e. learning ability,
delayed recall, retention of words/forgetting rate and recognition ac-
cording to previous studies (Witte et al., 2014, Kobe et al., 2017), with
the German version of the California Verbal Learning Task (CVLT)
(Niemann et al., 2008). The investigator read out loud a wordlist, con-
sisting of 16 words and participants had to remember as many words as
possible. Words belonged to one of four categories (e.g. spices, drinks,
toys). The same list was repeated over 5 consecutive immediate recall
trials (trials 1–5). Then, a second distractor list was presented in the same
way for one trial. Afterwards, an immediate free recall trial occurred and
was followed by a cued recall trial, where participants were asked to
recall words according to the four categories. After a delay of 15–20min
in which participants underwent anthropometric measurements (see
below), they were asked to recall the words of the ﬁrst list in a long
delayed free recall trial. Subsequently, the investigator read out loud a
list of 48 words in a recognition trial and participants had to decide
whether the word belonged to list A (yes/no-answer). The outcome
"Learning ability" was deﬁned as sum of correctly given words after trials
1–5. “Delayed recall"was the number of correct words in the long delayed
recall trial. “Forgetting rate" was calculated by subtracting the number of
correct words of trial 5 from the delayed free recall. “Recognition" was
calculated by the number of correctly identiﬁed words of the recognition
trial minus false-positives. Two parallel versions at random order were
used at baseline and follow up. Assessment time of day for cognitive
testing did not correlate with baseline task performance in the CVLT (all
p > 0.05) and assessment time of day did not change between baseline
and follow up dependent on group (p ¼ 0.77).
In addition, attention and mental ﬂexibility were assessed using the
Trail Making Task (TMT) (Reitan and Wolfson, 1985). Brieﬂy, partici-
pants had to connect numbers or letters that were randomly distributed
over a sheet of paper with a pencil in ascending order as fast as possible.
Part A comprised numbers (1–25), in part B participants had to alternate
between numbers (1–13) and letters (A–L). Outcome measures were re-
action time (in seconds) to complete part A and part B, and their ratio
(time part B / time part A).
ModBent task
Pattern recognition performance was assessed with the ModBent Task
(Brickman et al., 2014). The ﬁrst part of this computer-based test con-
sisted of 41 trials. During each trial the participants were asked to
memorize a so-called Lissajous-ﬁgure that was presented on screen for
10 s. A Lissajous-ﬁgure is a sinusoidal curve derived in a mathematically
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controlled manner and ﬁgures differ in order, e.g. number of horizontal
and vertical nodes (see Figure 2). After a delay of 1 s participants had to
choose the previously presented ﬁgure out of two ﬁgures from the same
Lissajous-order. The task included 41 different ﬁgures and different
parallel versions were used at baseline and follow-up. The second part of
the ModBent Task contained 82 recognition trials. Participants were
presented one ﬁgure at a time and had to decide whether the object was
identical to any previous target stimulus. Outcomemeasures included the
sensitivity index (d’), calculated as d’¼ z (hits) - z (false alarms), ac-
cording to signal detection theory (Hochhaus, 1972) and mean reaction
time in correct rejection trials (Brickman et al., 2014). Further details are
provided in the supplementary material. Five participants had to be
excluded from the analysis due to systematic response bias (always
pressing “yes” or “no”) in either baseline or follow-up measure, one had
to be excluded due to a program error at follow-up, leaving n¼ 44 for
analysis.
Blood parameters and anthropometric measurements
Overnight fasted blood samples were collected and immediately sub-
mitted to the laboratory. To assess glucose-metabolism, glycated hemo-
globin (HbA1c, Institute for Medical Diagnostics (IMD) Berlin-Potsdam,
Germany), glucose (Cobas 8000, Roche diagnostics, Mannheim, Germany)
and insulin (Liaison, DiaSorin, Dietzenbach, Germany) were measured. In
addition, liver parameters, lipid-metabolism (total cholesterol, high- and
low-density lipoproteins (HDL, LDL), triacylglycerides), inﬂammatory
markers (interleukin 6 (IL-6) and high-sensitive C-reactive protein
(hsCRP)) were determined by standard clinical chemistry procedures
(Cobas 8000, Roche Diagnostics, Mannheim; Germany).Main target pa-
rameters as tumor necrosis factor (TNF α, interassay coefﬁcient of varia-
tion (CV) 2.10–9.01%), brain derived neurotrophic factor (BDNF, CV
5.90–15.97%) (both fromR&D Systems, Wiesbaden, Germany), leptin (CV
6.06–10.58%; Mediagnost, Reutlingen, Germany) and insulin-like growth
factor 1 (IGF-1, CV 3.5–7.2%; iSYS, IDS, Frankfurt/Main, Germany) were
measured by immunoassays. Blood count measurements were performed
by the SYSMEX system (Norderstedt, Germany). IL-6 measures below
detection limit were set to 1.50 pg/ml (lowest value). Due to technical
reasons, HbA1c measures were missing in 3 subjects (n (resveratrol)¼ 2; n
(placebo)¼ 1) and insulin in one resveratrol subject.
Unconjugated resveratrol and its main metabolites (sulfated, glu-
curonated, sulfo-glucuronated) were determined in serum samples by 3S-
Pharma, Bucharest, Romania using high performance liquid
chromatography. Details can be found elsewhere (Liu et al., 2010; Ser-
gides et al., 2016). All values below detection threshold were set to 0.
Furthermore, no baseline serum samples were available for two partici-
pants of the resveratrol group. Therefore, values were substituted by
group medians (i.e. 0).
Anthropometric measures included weight (kg), height (m), waist-
and hip-circumference (cm) to calculate body-mass index (BMI, kg/m2)
and waist-hip-ratio (WHR). Furthermore, a bioelectrical impedance
analysis (BIA) was performed to assess percentage of body-fat (Biacorpus
RX4004M with phasertab-electrodes, MediCal Healthcare GmbH, Karls-
ruhe, Germany). The measurement was bilateral with eight electrodes
(two attached to each hand and foot of the participant). Systolic and
diastolic blood pressure was measured according to guidelines of the
European Society of Hypertension (O'Brien et al., 2005).
Confounder assessment
Apolipoprotein E (ApoE) genotyping was performed with genomic
DNA extracted from peripheral blood samples at The Medical Research
Centre of the University of Leipzig. The rs7412 and rs429358 poly-
morphisms were genotyped using the KASPar SNP Genotyping assay
(KBioscience Ltd, Hoddesdon, UK) according to the manufacturer's in-
structions on an ABI Prism 7500 Sequence Detecting System (Life tech-
nologies, Foster City, CA, USA). Genotype frequencies were in Hardy-
Weinberg-equilibrium. To assess genotyping reproducibility, a random
10% selection of the sample was re-genotyped in both SNPs; all geno-
types matched initial designated genotypes. To assess subjective cogni-
tive decline (SCD), participants were asked about a recent memory
decline and if they worried about those changes (Jessen et al., 2014).
Participants who answered both questions in the afﬁrmative were clas-
siﬁed as having SCD. In addition, subjects ﬁlled in computer-aided
questionnaires about education (6 levels: no degree, 9, 10, 12, 13 years
of school, university degree), depressive symptoms (German version of
Beck’s Depression Inventory (BDI; Hautzinger et al., 1994), a
multiple-choice vocabulary intelligence test (MWT-B; Lehrl, 1999), the
International Physical Activity Questionnaire (IPAQ; IPAQ Group, 2002),
the Trier Inventory for chronic stress (TICS; Schulz et al., 2004), Pitts-
burgh Sleep Quality Index (PSQI; Buysse et al., 1989), and a validated
Food Frequency Questionnaire (FFQ) used within the German Health
Examination Survey for Adults (DEGS1) of the Robert-Koch Institute
(Robert-Koch-Institute, 2009; Haftenberger et al., 2010; Gosswald et al.,
2012).
Final sample for analysis
    Blood parameters (N = 27)
    Neuropsychological testing (N = 27)
    3T- MRI (N = 22 ), 7T- MRI (N = 26)
Lost to Follow-up (N = 3)
    Decreasing Eye Sight (N = 1)
    Allergic Reactions (N = 1)
    Reason unknown (N = 1)
Placebo group (N = 30)
    Received treatment (N = 30)
Lost to Follow-up (N = 4)
    Excluded (Medication) (N = 2)
    Other (N = 2)
Final sample for analysis
    Blood parameters (N = 26)
    Neuropsychological testing (N = 26)
    3T- MRI (N = 23 ), 7T- MRI (N = 24)
Excluded (N = 133)
    Not meeting inclusion criteria (N = 66)
    Declined to participate (N = 61) 
    Other reasons (N = 6)
Resveratrol group (N = 30)
    Received treatment (N = 30)
Follow-up
Analysis
Assessed for eligibility
(N = 193)
Randomized
(N = 60)
Allocation
Enrollment
Figure 1. Flowchart Participants. 193 participants
were assessed for eligibility. 133 had to be excluded
because they did not meet inclusion criteria (n¼ 66),
declined to participate (n¼ 61) or due to other rea-
sons (n¼ 6). 60 participants could then be random-
ized to placebo (n¼ 30) and resveratrol group
(n¼ 30). Three participants receiving resveratrol
were lost to follow-up because of a decrease in
eyesight (n¼ 1), an allergic reaction (n¼ 1) and
without further speciﬁcations (n¼ 1). Two partici-
pants belonging to the placebo group had to be
excluded after baseline assessment, because of intake
of medication that did not meet inclusion criteria of
the study protocol. Finally, analysis for blood pa-
rameters was available for n¼ 26/24 (resveratrol/
placebo), neuropsychological tests n¼ 27/26 and
magnetic resonance imaging (MRI) with good image
quality at 3 Tesla (3T) n¼ 22/23 and at 7 T n¼ 26/
24.
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Magnetic resonance imaging (MRI) acquisition and analysis
Anatomical imaging
AnatomicalMRI for hippocampal volumetrywas acquired at a Siemens
Magnetom7 T system (SiemensHealthineers, Erlangen, Germany) using a
32-channel head array coil (NOVA Medical Inc., Wilmington MA, USA).
High-resolution T1-weighted images were acquired using a MP2RAGE
(Marques et al., 2010)protocol (repetition time (TR)¼ 5000ms; inversion
time (TI) 1/2¼ 900/2750ms; echo time (TE)¼ 2.45ms; image matrix:
320" 320" 240; voxel size 0.7mm" 0.7mm" 0.7mm; ﬂip angle
1/2¼ 5#/3#; parallel imaging using GRAPPA (Griswold et al., 2002) with
acceleration factor¼ 2). T2-weighted imaging slabs perpendicular to the
anterior-posterior axis of the hippocampus were acquired using a
Turbo-Spin Echo Sequence (TR¼ 13000ms; TE¼ 14ms; image matrix:
384" 384; 50 slices; voxel size: 0.5mm" 0.5mm" 1mm; refocusingﬂip
angle¼ 120#; turbo factor¼ 8; parallel imaging using GRAPPA with ac-
celeration factor¼ 2). Brieﬂy, the bias-ﬁeld corrected T1-weighted im-
ages provided by the MP2RAGE sequence were skull-stripped using CBS
Tools (Bazinet al., 2014) andprocessedwith theFreeSurfer imageanalysis
suite (http://surfer.nmr.mgh.harvard.edu/) in a longitudinal stream
(Reuter et al., 2012). Hippocampal subﬁeld segmentation was performed
using theMP2RAGEandTSE images in amultimodal approach,whichwas
initialized by the output of the longitudinal stream (Iglesias et al., 2015).
For details, see Supplementary information. Out of 13 subﬁelds and
structures segmented by the algorithm, we considered six main subﬁelds
(Cornu Ammonis 1, 2/3, 4, dentate gyrus, presubiculum and subiculum)
for further analysis (Erickson et al., 2011; Brickman et al., 2014). Four
participants had to be excluded from 7T data analysis (n¼ 1 not MRI
suitable at follow-up, n¼ 2 withdrew 7T MRI consent at follow-up, n¼ 1
poor data quality), leaving 49 for analysis (n¼ 25 resveratrol, n¼ 24
placebo).
Diffusion-weighted imaging analysis
Diffusionweighted images (DWI)were collected at 7Twitha single shot
echo planar imaging (EPI) sequence (TR¼ 6000ms; TE¼ 62.8ms; image
matrix¼ 128" 128,60slices; voxel size¼ 1.2mm" 1.2mm" 1.2mm,67
diffusion directions, b¼ 1000 s/mm2, parallel imaging usingGRAPPAwith
acceleration factor¼ 2). The imaging slab was chosen to cover the bilateral
hippocampus in all participants. In order to correct for image distortions, an
additional volume with no diffusion weighting (b¼ 0) but with opposite
Baseline Follow-up9 Age > 60 years 
9 22 < BMI < 40 kg/m2
9 MMSE > 26
8 Stroke, diabetes mellitus, psychiatric 
    or severe internal disease
8 medication acting on the CNS
8 antioxidative supplements
8 MRI contraindications 
8 >50g alcohol or >6 coffee cups/day
8 >10 cigarettes/day
Hippocampus (7T) 
T2-weighted TSE (0.5 x 0.5 x 1mm3)
T1-weighted MP2RAGE (0.7 x 0.7 x 0.7 mm3)
Mean diffusivity from DWI (1.5 x 1.5 x 1.5 mm3)
Presentation of target 
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R
Figure 2. Study design and outcome measures. Healthy elderly subjects were screened for eligibility based on inclusion and exclusion criteria, and 60 participants
were randomly assigned to either resveratrol or placebo group. Baseline and follow-up measurements included neuropsychological testing, fasting blood draw
(glucose- and lipid-metabolism, inﬂammatory markers, neurotrophic factors), anthropometric measures (weight, height, waist- and hip-circumference, body fat), as
well as multimodal neuroimaging. 27 participants receiving resveratrol and 26 participants receiving placebo completed 26 weeks of pill intake and were included in
primary analyses of verbal memory performance. In addition, pattern recognition performance was tested using the ModBent task. Volume and mean diffusivity of
hippocampus subﬁeld was assessed using high-resolution MRI at 7 T. Abbreviations: BMI: body mass index, CA: cornu ammonis, CNS: central nervous system, DG:
dentate gyrus, DWI: diffusion weighted imaging, MMSE: Mini Mental Status Examination, MP2RAGE: Magnetization-Prepared 2 RApid Gradient Echoes MRI: magnetic
resonance imaging, T: Tesla, TSE: turbo spin echo.
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phase-encoding direction was acquired. Brieﬂy, diffusion weighted images
were preprocessed using FSL (Smith et al., 2004) and mean diffusivity
(MD)-slabswere registered to the T1-weightedMP2RAGE image using CBS
Tools (Bazin et al., 2014) and ANTS (Avants et al., 2011). For details, see
Supplementary information. Then, median hemisphere-averaged values
ofMDvalues> 0and< 0.002mm2/sof the sixhippocampus subﬁeldswere
extracted to increase signal-to-noise ratio. One additional participant had to
be excluded based on poor data quality, leaving 48 for analysis (n¼ 25
resveratrol, n¼ 23 placebo).
Resting state functional connectivity
To achieve whole brain coverage resting state fMRIwas performed on a
3TSiemensVerio Scannerwith a 32 channel head coil. T1-weighted images
were acquired using an MP-RAGE sequence and the Alzheimer's Disease
Neuroimaging Initiative standard protocol (TR ¼ 2300 ms; TI ¼ 900 ms;
TE ¼ 2.98 ms; image matrix ¼ 256 " 240 " 176; voxel
size¼1.0mm"1.0mm"1.0mm;ﬂipangle¼9#. T2*-weighted functional
images were acquired using a multi-band echo-planar-imaging sequence
with the following parameters: TR ¼ 1400 ms; TE ¼ 30 ms; image
matrix¼ 88" 88; 64 slices; voxel size¼ 2.3 mm" 2.3 mm" 2.3 mm; ﬂip
angle¼ 69#; multiband factor¼ 4; 550 volumes).
Brieﬂy, preprocessing of the functional images was performed using
FSL and included correction for motion, distortion and further nuisance
variables and a bandpass-ﬁltering between 0.01 and 0.1 Hz. FreeSurfer-
derived masks of the left and right hippocampus at 3T images, divided
into anterior and posterior division (Lerma-Usabiaga et al., 2016), were
registered to the functional images (2mm isotropic) and connectivity
was estimated by correlating the mean time series in left and right pos-
terior and anterior hippocampus with all other voxels in the brain.
Connectivity maps were standardized, transformed to MNI space using
ANTS (Avants et al., 2011) and smoothed with a Gaussian kernel of 6mm
full-width-at-half-maximum. A reproducible pipeline is available at
https://github.com/fBeyer89/RSV_rsanalysis, for further details see
Supplementary Information. In addition, as motion is an important
confounder in rs-fMRI we performed a sensitivity analysis following the
scrubbing approach described in (Power et al., 2014). To verify the se-
lection of anterior and posterior hippocampus regions of interest, we
calculated the within-subject differences of anterior and posterior hip-
pocampus connectivity for the right and left hippocampus separately
using available baseline MRI data (n¼ 51, 2 excluded due to strong head
motion deﬁned as exceeding a maximum framewise displacement of
3mm). For longitudinal analysis, another 6 participants were excluded
from analysis due to motion, leaving 45 for analysis (n¼ 22 resveratrol,
n¼ 23 placebo).
Statistical analysis
Main analysis
To test the effects of resveratrol on memory performance, a multi-
variate repeated-measures analysis of variance (MANOVARM) was con-
ducted with time (baseline, follow-up) as within-subject factor, group
(resveratrol, placebo) as between-subject factor and the four primary
outcome measures of the CVLT test (learning ability, forgetting rate,
delayed recall and recognition) as dependent variables. The multivariate
design allowed to assess potential intervention effects on the four out-
comes with the same model. We additionally performed paired sample t-
tests/Wilcoxon signed rank tests for within-group pre-post comparison
and corrected for age, sex and education in a second analysis, as these
variables are known to inﬂuence cognitive performance.
Exploratory analyses
In addition, performance of TMT and ModBent task, as well as
changes in anthropometrics and blood parameters were compared using
ANOVARM to check for time and group effects, except for inﬂammatory
markers (hsCRP, IL-6, TNF-a) which were tested using non-parametric
tests on the differences between baseline and follow-up due to their
skewed distribution. Volumes and MD of hippocampal subﬁelds were
compared using MANOVARM. Paired samples t-test and Wilcoxon signed
rank test were used for within group comparisons as appropriate. Addi-
tionally, independent sample t-tests, Mann Whitney U-tests or χ2-tests
were performed to check for baseline differences between groups. All
variables were checked for assumptions of normal or near-normal dis-
tribution (unimodal, jskewnessj and jkurtosisj< 1). Signiﬁcance level
was set to α< 0.05 unless indicated otherwise (two-sided). Statistical
analysis was performed using SPSS (IBM, version 24).
Whole-brain connectivity analyses
First, anterior-posterior connectivity difference maps were tested
using a one-sample-t-test in RANDOMISE with positive and negative
contrast. Then, to test time by intervention-group interaction we calcu-
lated post – pre-difference maps of left, right, anterior and posterior
hippocampus connectivity and compared them between groups using a
two-sample independent t-test with FSL’s RANDOMISE (5000 permuta-
tions) (Winkler et al., 2014). Signiﬁcant results were based on
threshold-free cluster enhanced (TFCE), family wise error (FWE) cor-
rected p-values of p< 0.05 and differences were visualized based on
thresholded t-maps with jtj> 3.
Results
Baseline characteristics
At baseline, the intervention and placebo group did not differ
signiﬁcantly in sex, age, years of education, MMSE, ApoE-status, SCD,
depressive symptoms, verbal intelligence (measured with a vocabulary
test), perceived stress, sleep quality, and BMI (see Table 1 for details). All
participants met the MMSE inclusion criterion.
Compliance and change in mood and lifestyle factors
According to self-reported diaries and capsule counts, adherence to
the capsule intake instructions was overall high in both groups (mean pill
intake of > 94% $ 0.06; range: 74–100%). In serum, resveratrol and its
metabolites could not be detected at baseline except in one participant of
the resveratrol group showing a very low value of unconjugated resver-
atrol. At follow-up, there was a highly signiﬁcant increase in serum
measures of resveratrol and its metabolites in the intervention group,
whereas values were again low in the placebo group (ANOVARM, all F(1,
51) > 21, all p < 0.001, Table 2). While the biological activity of
resveratrol and its metabolites is still incompletely understood, serum
measures might be regarded as rather short-term markers of resveratrol
intake (see Walle 2011 for further discussions). Evaluation of
self-reported FFQ data did not indicate that participants in either group
got high amounts of dietary resveratrol across the intervention/placebo
period (see Supplementary Information).
Depressive symptoms, perceived stress, sleep quality and diet did not
change during the intervention period according to self-reported infor-
mation (all p> 0.49). However, there was a signiﬁcant time effect on
physical activity showing less physical activity at follow-up in both
groups (F(1, 51)¼ 13.068, p< 0.001, n¼ 53). This effect remained after
exclusion of eight participants, whose data was rated as implausible due
to extreme over-reporting (F(1, 51)¼ 12.449 p< 0.001, n¼ 45, Supple-
mentary S1). Please note that after baseline assessments the IPAQ data
entry format was changed with the intention to avoid over-reporting:
After baseline evaluation a tendency towards over-reporting was
noticed that was related to the data entry format as hours and minutes.
The correct way to enter the data for a 90min workout had been:
hours¼ 1, minutes¼ 30. However, during data curation we noticed that
participants, who engaged in an activity for 3 h entered in the ﬁrst ﬁeld
indicating the hours “3” and in the second ﬁeld indicatingminutes “180”,
obviously transforming hours to minutes. To avoid such an over-
reporting the data entry format for follow-up was changed to minutes
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only. Unfortunately, this might have introduced a systematic bias, as the
subjective evaluation of an activity given in minutes only might be
different from a time given in hours and minutes.
Memory performance
There was no signiﬁcant time by intervention group interaction in the
main analysis of performance of the CVLT after the intervention/placebo
period according to MANOVARM (F(4, 48)¼ 1.29, p¼ 0.29; Figure 3).
Correcting for age, sex and education did not change this result (F(4,
45)¼ 1.40, p¼ 0.25). We observed a signiﬁcant overall effect of time (F(4,
48)¼ 2.94, p¼ 0.03) showing higher learning (F(1, 51) ¼ 4.40, p ¼ 0.041)
and delayed recall (F(1, 51)¼ 4.06, p ¼ 0.049) and a trend for lower
forgetting rate (F(1, 51) ¼ 3.39, p ¼ 0.072) in the whole group at follow-
up. In addition, we detected an effect of the order of the parallel test
versions that were used in the CVLT (time by order, F(4, 46) ¼ 3.2,
p ¼ 0.021). This might have contributed to our results, as random
assignment to the parallel versions at baseline yielded in a different
distribution of version order between groups (resveratrol/placebo, order
1: n¼ 18/9, order 2: n¼ 9/17). In exploratory analyses separately for the
two version order subgroups, we did not observe signiﬁcant time by
group interactions (all p > 0.6).
We found no effects of APOE-genotype.
With regard to pattern recognition memory performance measured
using the ModBent task, we observed a trend for a time by intervention
group interaction for d' (ANOVARM F(1, 42)¼ 3.46, p¼ 0.07; Figure 4).
Within-group analyses revealed decreases in d' in the placebo group
(t(21)¼ 2.24, p¼ 0.036), whereas the resveratrol group did not change
(p¼ 0.8). Reaction times did not change signiﬁcantly (ANOVARM p> 0.8).
For the Trail making test, there was a signiﬁcant effect of time for part
A (ANOVARM, F(1, 51)¼ 5.1, p¼ 0.028), indicating decreases in reaction
times at follow up in the whole group (Table 2). No further time effects
for part B and for ratio B/A nor group by time interactions for the three
subscores emerged (ANOVARM, time: all p> 0.12, time by intervention
group interactions: all p> 0.4). Correcting for age and sex did not change
these results.
Fasting blood levels and anthropometric measures
For details on blood measures, see Table 2. There was no signiﬁcant
time by intervention group interaction for HbA1c levels (ANOVARM F(1,
48)¼ 1.83, p¼ 0.18; Figure 5, Table 2). Also within groups no signiﬁcant
changes of HbA1c were observed (resveratrol and placebo p> 0.2). In an
exploratory analysis, we considered ‘change in physical activity’, ‘change
in BMI’ as well as ‘change in caloric intake’ (as a proxy of dietary intake)
as covariates in the model. When adding these covariates, there was a
trend for a time by intervention group interaction effect on HbA1c values,
indicating reductions in the resveratrol group at follow up (F(1, 45) ¼ 3.9,
p¼ 0.054). When additionally adjusting for age and sex, the interaction
term reached signiﬁcance (F(1, 43) ¼ 4.67, p ¼ 0.036).
In addition, there was a signiﬁcant time effect for fasting glucose
(ANOVARM F(1, 51)¼ 13.97, p< 10-3), showing increases in glucose
levels (whole group, mean increase: 0.24mmol/L $ 0.46 SD), while in-
sulin did not change signiﬁcantly (all p> 0.27). Further comparisons
revealed a signiﬁcant time by intervention group interaction for choles-
terol (ANOVARM F(1, 51)¼ 9.47, p¼ 0.003), showing increases in the
resveratrol group (p¼ 0.006, t(26)¼ 3.0), while values of the placebo
group slightly decreased (trend, p¼ 0.087). A signiﬁcant decrease over
time was observed for IGF-1 and BDNF levels in the whole group (all
ANOVARM, IGF-1: F(1, 51)¼ 11.442, p¼ 0.001, BDNF: F(1, 51)¼ 16.463,
p< 0.001). The decline in IGF-1 was more pronounced again in the
resveratrol group (t(26)¼ 3.68, p< 10% 3).
Considering inﬂammatory markers, we noticed overall increases in
hsCRP, IL-6 and TNF-α in both groups (Wilcoxon-signed rank test, hsCRP,
Z¼ 2.26, p¼ 0.024; IL-6, Z¼ 3.88, p< 10% 3; TNF-a, Z¼ 2.73, p¼ 0.006;
Table 2). In addition, IL-6 levels showed larger increases over time in the
resveratrol group compared to placebo (Mann-Whitney U test, Z¼ 2.20,
p¼ 0.028).
At follow-up, participants also showed a signiﬁcant increase in body
weight and body fat in both groups. They gained on average 0.55 kg
weight and 0.54% fat (weight: ANOVARM F(1, 51)¼ 4.06, p¼ 0.049; body
fat: ANOVARM F(1, 51)¼ 5.84, p¼ 0.019), which was more pronounced in
the resveratrol group (Table 2). An overall effect of time on diastolic
blood pressure was not signiﬁcant (p¼ 0.11), yet within-group com-
parisons indicated a decrease in diastolic blood pressure in the placebo
group (Z¼ 2.06, p¼ 0.039). No further changes were observed.
Hippocampus subﬁeld measures
MANOVARM revealed no signiﬁcant time (F(6, 42)¼ 0.96, p¼ 0.46) or
time by intervention group effect (F(6, 42)¼ 0.46, p¼ 0.84) on hippo-
campus subﬁeld volumes (Supplementary Table S1). Similar results were
observed for MD (MANOVARM, time: F(6, 41)¼ 1.20, p¼ 0.33, time by
intervention group: F(6, 41)¼ 0.32, p¼ 0.93, Supplementary Table S2),
however, MD values seemed to decrease with time in the subiculum and
presubiculum in both groups (Figure 6, univariate ANOVARM time effect:
subiculum p¼ 0.049, presubiculum p¼ 0.012). See Supplementary
Figures S1-S2 for details on subject’s variability.
Table 1
Baseline characteristics dependent on group. Data is given as mean $ standard
deviation (SD) and range (minimum – maximum). a) Two missing values (1
resveratrol, 1 placebo) due to missing blood samples b) Verbal intelligence was
measured using a vocabulary test c) presented values refer to the screening scale
for chronic stress with low values referring to low stress d) presented values refer
to the PSQI standard outcome; low values represent good quality of sleep e) Chi
Square Test f) Independent Sample t-test, g) Mann-Whitney test.
Parameter Resveratrol Placebo p-
value
n (female/male) 27 (14/13) 26 (14/12) 0.88 e
Age (years) 68.60 $ 4.92
(61–78)
67.54 $ 5.07
(60–77)
0.46 g
Education (years) 15.20 $ 3.8
(10–18)
15.46 $ 3.89
(9–18)
0.89 g
Mini Mental Status Examination
(score)
28.70 $ 1.2
(26–30)
28.88 $ 1.03
(26–30)
0.67 g
Apolipoprotein E Status (ApoE ε 4-
Carrier n, %) a
9, 34.6% 8, 32% 0.84 e
Subjective Cognitive Decline (n, %) Yes¼ 10
(37%)
No¼ 17
(63%)
Yes¼ 10
(38.5%)
No¼ 16
(61.5%)
0.91 e
Beck’s Depression Index (score) 4.7 $ 3.2
(0–13)
5.46 $ 4.84
(0–16)
0.48 f
Verbal Intelligence b 119.8 $ 12.0
(97–143)
117.2 $ 13.5
(94–143)
0.46 f
Stress (values 0–48) c 8.93 $ 5.31
(0–21)
11.42 $ 6.2
(0–26)
0.178 g
Sleep (values 0–21) d 5.19 $ 3.08
(2–13)
5.42 $ 2.89
(1–12)
0.622 g
Body-Mass Index (BMI, kg/m2) 26.5 $ 3.8
(22.2–36.2)
26.9 $ 4.6
(21.1–37.6)
0.86 g
Primary outcome measures of the California Verbal Learning Task
Learning sum 44.52 $ 9.1
(18–62)
45.96 $ 8.9
(22–65)
0.69 g
Delayed recall 9.22 $ 2.9
(3–16)
9.08 $ 2.7
(4–15)
0.98 g
Forgetting rate 1.81 $ 3.3
(-5–7)
2.58 $ 2.5
(-3–7)
0.47 g
Recognition 12.56 $ 3.1
(4–16)
12.54 $ 2.6
(7–16)
0.67 g
Secondary outcome measures
ModBent (d’) 0.95 $ 0.66
(0–2.95)
1.34 $ 0.85
(-0.42–3.17)
0.052 g
Trail Making Task A
(in seconds)
43 $ 13
(28–84)
41 $ 14
(16–79)
0.66 g
Trail Making Task B
(in seconds)
89 $ 29
(45–161)
80 $ 25
(40–127)
0.33 g
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Resting state functional connectivity of the hippocampus
At baseline, the anterior hippocampus was signiﬁcantly stronger
connected to the parahippocampal gyrus and the temporal lobe than the
posterior hippocampus (TFCE, FWE-corrected, p< 0.05; Figure 7). The
posterior hippocampus was more connected to precuneus and angular
gyrus but this effect did not survive correction for multiple comparisons
(TFCE, uncorrected p< 0.05). The results were similar for both
hemispheres.
In the longitudinal analysis, we found no signiﬁcant difference in
hippocampus connectivity change between the intervention and control
group at a FWE-corrected level of p< 0.05 using TFCE. These results
remained unchanged after removing volumes affected by motion in 28
subjects.
Discussion
In this randomized controlled interventional study we did not detect
signiﬁcant effects of 26 weeks resveratrol intake compared to placebo on
verbal memory performance measured using the CVLT in healthy elderly.
In exploratory analyses, we observed a non-signiﬁcant trend for stable
performance in a pattern recognition task in the resveratrol group, while
performance decreased in the placebo group. HbA1c levels as well as
hippocampus volume, microstructure and functional connectivity did not
change signiﬁcantly compared to placebo. In contrast, we noticed in-
creases in serum cholesterol only in the resveratrol group and increases in
weight, body fat, fasting glucose and inﬂammatory markers, as well as
decreases in physical activity and neurotrophic factors in both groups.
Table 2
Changes in fasting serum levels and anthropometric measures according to groups. Bold numbers indicate signiﬁcant differences. Data is given as mean $ standard
deviation and range (minimum – maximum). a) Three participants were excluded due to missing values b) One participant excluded due to technical problems c)
Dependent Samples T-Test, d) Wilcoxon Sign-Rank Test, e) all values below lower level of detection; Abbreviations: BDNF¼ brain-derived neurotrophic factor,
HbA1c¼ glycated hemoglobin, HDL¼ high-density lipoprotein, hsCRP¼ high-sensitivity C-reactive protein, IGF¼ insulin-like growth factor, LDL¼ low-density lipo-
protein, MET¼Metabolic Equivalent, TNF¼ tumor-necrosis factor
Parameter Resveratrol (n¼ 27) Placebo (n¼ 26)
Pre Post p, T(df) or p, Z Pre Post p, T(df) or p, Z
HbA1c (%) a 5.63 $ 0.25
(5.23–6.27)
5.61 $ 0.30
(5.04–6.22)
0.202 c 5.55 $ 0.23
(5.14–6.21)
5.56 $ 0.2
(5.19–5.97)
0.564, c
Glucose (mmol/L) 5.17 $ 0.45
(4.38–6.05)
5.45 $ 0.66
(4.37–7.36)
0.008, % 2.67 d 5.36 $ 0.57
(4.42–6.91)
5.55 $ 0.57
(4.35–6.81)
0.029, % 2.19, d
Insulin (pmol/L) b 61.5 $ 39.41
(12.10–157.30)
72.6 $ 50.11
(9.10–231.40)
0.3d 65.36 $ 56.67
(13.60–286.80)
59.68 $ 39.41
(14.30–193.70)
0.53, d
Total Cholesterol (mmol/L) 5.74 $ 0.92
(4.15–7.66)
6.02 $ 1.07
(4.10–8.23)
0.006, % 3.0 (26) c 5.99 $ 0.93
(4.74–8.32)
5.70 $ 0.83
(3.92–7.38)
0.087, c
LDL/HDL-ratio 2.5 $ 1.2
(0.82–4.86)
2.6 $ 1.2
(0.86–5.11)
0.7 c 2.3 $ 0.79
(0.69–4.04)
2.1 $ 0.7
(0.70–3.39)
0.1, c
Triacylglycerides (mmol/L) 1.22 $ 0.71
(0.57–3.60)
1.37 $ 0.87
(0.62–4.19)
0.77 d 1.16 $ 0.61
(0.53–2.89)
1.15 $ 0.45
(0.59–2.23)
0.35, d
Interleukin-6 (pg/ml) 2.25 $ 1.35
(1.50–6.76)
3.5 $ 2.16
(1.50–9.88)
0.002, % 3.10 c 2.53 $ 3.25
(1.50–18.21)
3.12 $ 4.2
(1.50–23.17)
0.032, % 2.143, d
HsCRP (mg/L) 2.33 $ 2.22
(0.28–8.90)
4.9 $ 8.02
(0.47–42.46)
0.022, % 2.28 c 1.93 $ 2.39
(0.16–11.27)
3.82 $ 11.28
(0.24–58.58)
0.39, d
TNF-α (pg/ml) 0.89 $ 0.29
(0.57–1.77)
0.99 $ 0.43
(0.51–2.29)
0.099 d 0.76 $ 0.21
(0.48–1.20)
0.81 $ 0.2
(0.38–1.08)
0.020, % 2.329 d
Leptin (μg/L) 13.46 $ 13.15
(0.57–50.73)
13.37 $ 12.82
(0.2–48.31)
0.719 d 11.43 $ 8.22
(1.01–24.25)
11.92 $ 9.11
(1.47–31.90)
0.675, d
IGF-1 (μg/L) 106.5 $ 24.5
(67.10–155.90)
96.2 $ 24.9
(57.80–138.90)
0.001, 3.7 (26) c 107.9 $ 34.5
(50.30–189.80)
103.3 $ 32.5
(38.20–172.70)
0.19 c
BDNF (ng/ml) 22.21 $ 6.12
(11.1–41.5)
25.48 $ 7.7
(14.3–46.4)
0.015, % 2.43 d 26.3 $ 6.4
(10.9–39.8)
29.6 $ 6.1
(17.0–41.5)
0.014, % 2.451, d
Unconjugated Resveratrol (ng/mL) 0.05 $ 0.18
(0.0–0.95)
4.90 $ 5.57
(0.0–19.52)
0.001, -3.92 d 0.16 $ 0.81
(0.0–4.13)
0.0 $ 0.0 e 0.32, % 1.00 d
Glucuronated Resveratrol (ng/mL) 0.26 $ 0.50
(0.0–1.94)
894.19 $ 593.07
(0.89–2308.54)
0.001, -4.52 d 0.21 $ 0.50
(0.0–2.13)
0.73 $ 0.65
(0.0–2.88)
0.007, -2.69 d
Sulfated Resveratrol (ng/mL) 0.39 $ 0.79
(0.0–2.42)
336.16 $ 217.91
(0.0–757.46)
0.001, -4.52 d 0.12 $ 0.36
(0.0–1.39)
0.08 $ 0.29
(0.0–1.34)
0.50, % 0.67 d
Sulfo-Glucuronated Resveratrol (ng/mL) 0.59 $ 0.99
(0.0–4.24)
155.85 $ 168.25
(1.26–748.73)
0.001, -4.35 d 0.32 $ 0.49
(0.0–1.60)
0.21 $ 0.33
(0.0–1.37)
0.49, % 0.686 d
Weight (kg) 75.54 $ 14.29
(57.0–112.0)
76.35 $ 14.61
(57.4–118.0)
0.062, % 1.95 c 76.02 $ 17.32
(52.0–137.0)
76.29 $ 17.36
(52.6–138.0)
0.279, d
Body-Mass Index (kg/m2) 26.76 $ 3.91
(22.2–36.2)
26.95 $ 4.06
(21.5–38.1)
0.113 d 26.94 $ 4.46
(21.1–37.6)
27.01 $ 4.28
(22.0–37.7)
0.424, d
Body fat (%) 29.07 $ 8.07
(15.7–42.8)
29.71 $ 7.97
(11.9–43.1)
0.028, % 2.20 d 30.43 $ 8.47
(14.8–47.8)
30.87 $ 8.31
(16.3–44.9)
0.073, % 1.791 d
Systolic Blood Pressure (mm Hg) 139.10 $ 16.17
(109.0–173.3)
139.95 $ 17.49
(116.7–185.3)
0.748 c 141.35 $ 17.63
(115.3–191.3)
138.08 $ 15.76
(112.7–183.7)
0.174, d
Diastolic Blood Pressure (mm Hg) 86.30 $ 8.86
(68.0–102.0)
85.89 $ 7.65
(74.0–101.0)
0.773, c 89.92 $ 11.40
(66.0–113.0)
87.38 $ 10.86
(70.0–118.0)
0.039, % 2.061 d
Trail Making Task A (sec) 42.65 $ 12.83
(27.8–83.6)
38.96 $ 17.83
(18.68–112.62)
0.15, d 40.66 $ 13.72
(16.0–79.0)
35.90 $ 19.18
(16.56–54.72)
0.16, d
Trail Making Task B (sec) 88.56 $ 28.88
(45.4–160.9)
86.08 $ 28.06
(42.0–156.03)
0.52, d 80.32 $ 24.91
(40.0–127.4)
75.47 $ 25.38
(28.97–135.90)
0.27, d
Trail Making Task B/A 2.16 $ 0.73
(1.23–4.32)
2.43 $ 0.93
(1.25–4.25)
0.12, d 2.06 $ 0.53
(1.32–3.24)
2.14 $ 0.58
(1.40–3.73)
0.79, d
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Figure 3. Memory performance was measured with the California Verbal Learning Task, at baseline and after 6 months of either resveratrol (n¼ 27) or placebo intake
(n¼ 26). Multivariate analyses detected an overall positive effect of time in both groups (p¼ 0.03), but no time by intervention group interaction. Triangles represent
mean, error bars represent standard error (S.E.).
Figure 4. Pattern recognition memory performance, measured using the Mod-
Bent task, at baseline and after 6 months of either resveratrol (n ¼ 22) or pla-
cebo intake (n ¼ 22), showing a trend for a time by intervention group
interaction for sensitivity index d' (ANOVARM F(1, 42) ¼ 3.46, p ¼ 0.07). Tri-
angles represent mean, error bars represent standard error (S.E.).
Figure 5. Glycated Hemoglobin (HbA1c) levels. There was no signiﬁcant effect
of time on HbA1c levels between or within groups (ANOVARM p¼ 0.18,
F¼ 1.83, Paired samples t-tests p> 0.2). Triangles represent mean, error bars
represent standard error (S.E.).
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Resveratrol and memory performance
Considering verbal memory performance, we could not replicate
previous results of a signiﬁcant improvement after resveratrol compared
to placebo (Witte et al., 2014; Evans et al., 2017). An increase in memory
after resveratrol has also been reported in a variety of experimental an-
imal studies (Ingram et al., 2007; Dal-Pan et al., 2011; Kodali et al.,
2015). The signiﬁcant overall effect of time on learning, delayed recall
and forgetting rate can be a simple learning sequence effect and should
be interpreted with caution. However, in the current study we noticed
that the order of parallel test versions signiﬁcantly inﬂuenced test-retest
performance over time, and that version order was unevenly distributed
between groups at baseline. Though subgroup analyses stratiﬁed by
version order did not show signiﬁcant effects of the intervention,
test-retest effects and order effects might have introduced additional
confounding. In addition, some previous RCTs in healthy young adults, in
mild cognitive impairment patients or in patients with schizophrenia
were not able to show signiﬁcant effects of resveratrol on verbal memory
either (Turner et al., 2015; Wightman et al., 2015; Zortea et al., 2016;
Kobe et al., 2017; however note that sample sizes were not always
powered for cognitive effects).
It has also been discussed that polyphenols exert region-speciﬁc ef-
fects on the hippocampus, which would not necessarily translate into
improvements in simple word list learning, but rather in pattern recog-
nition memory (Brickman et al., 2014). Brickman et al. (2014) observed
that a ﬂavanol-containing diet improved reaction times in pattern
recognition memory assessed using the ModBent task, but not in verbal
memory performance of the modiﬁed Rey auditory learning task. Using
the same ModBent task, we observed a trend for resveratrol-induced
beneﬁts on pattern recognition measured with d prime (d’) (Hochhaus,
1972), but not in reaction times. Due to the small sample size available
for that analysis in our study and the exploratory nature, interpretation of
these results remain difﬁcult. In sum, future studies need to further
examine possible effects of resveratrol on memory before deﬁnite con-
clusions can be drawn.
Changes in biomarkers and lifestyle behavior
Considering possible mechanistic pathways, we could not conﬁrm
that resveratrol supplementation led to an improved long-term glucose
metabolism measured using HbA1c. Preclinical studies have reported
extensively that resveratrol improved glucose tolerance and insulin
sensitivity (for review, see Liu et al., 2014). However, this effect has not
been fully established in humans. More speciﬁcally, “at risk” populations
with overweight, obesity or type II diabetes did beneﬁt from resveratrol
intake (Timmers et al., 2011; Bhatt et al., 2012; Witte et al., 2014), while
those with normal weight did not (Yoshino et al., 2012; Poulsen et al.,
2013; Liu et al., 2014). Thus, resveratrol might have failed to induce net
improvements in glucose metabolism in our group comprising of healthy
participants with a wide BMI range (i.e., 21.1–37.6 kg/m2, none dia-
betic), which then would not have induced systematic structural or
cognitive changes in the whole group.
We furthermore observed unfavorable changes in a series of bio-
markers. Participants in both groups showed increases in weight and
body fat at follow-up, as well as lower physical activity. This might hint at
external factors, such as seasonal changes in physical exercise and diet
that occurred during intervention time. Considering that baseline as-
sessments were in spring and early summer, whereas follow-up assess-
ments took place in autumn and winter, a change to an unhealthier and
more sedentary lifestyle to the end of the year seems likely. Moreover,
participants might have drawn their own conclusions regarding study
participation: they might have thought of taking a “magic pill” and
therefore might have reduced their regular engagement in physical ex-
ercise and healthy dietary habits. Eventually, this behavioral change
might have provoked increases in low-grade inﬂammation as seen in
higher levels for hsCRP, IL-6 and TNF-a, and in glucose, but also de-
creases in neurotrophic factors IGF-1 and BDNF. In sum, all of these
factors are known to affect brain structure and function (Mattson et al.,
2004; Cherbuin et al., 2012; Wyss-Coray and Rogers, 2012), and could
therefore represent additional confounding factors. Note that HbA1c
levels did not increase in the resveratrol group despite increases in body
fat and BMI, and that the interaction term of time by group reached
signiﬁcance for changes in HbA1c in a model that accounted for changes
in physical activity, BMI and dietary caloric intake as well as age and sex.
The observed increase in cholesterol in the resveratrol group might
also be explained by higher dietary fat intake, as suggested by correla-
tions with increases in self-reported caloric intake (r¼ 0.41, p¼ 0.035)
and body fat mass (r¼ 0.5, p¼ 0.008) in that group. Yet, an increase in
cholesterol has also been observed previously in the resveratrol-group
only (Witte et al., 2014), and measures of resveratrol metabolites in
the current study at follow-up correlated with increases in cholesterol
(sulfated resveratrol, r¼ 0.43, p¼ 0.024; glucorunated resveratrol,
r¼ 0.39, p¼ 0.046). However, to our knowledge no
cholesterol-increasing effect of resveratrol has been described. Rather the
opposite has been reported e.g. in animals (Cho et al., 2008; Do et al.,
2008) and in human cell cultures (Voloshyna et al., 2013). We also
evaluated changes in HDL, LDL and LDL/HDL-ratio (which is an indicator
for the risk of coronary-heart diseases) according to current clinical
praxis and ﬁndings of the Framingham study (e.g. Nam et al., 2006). The
respective results did not raise clinical concerns. However, future studies
should take potential effects of resveratrol on cholesterol metabolism
into account.
Hippocampus microstructure and connectivity
We could not detect signiﬁcant effects of resveratrol compared to
placebo on volume and microstructure of the hippocampus. This is in line
with two previous trials using MRI at lower ﬁeld strength (Witte et al.,
2014; Kobe et al., 2017). Yet, this might contradict the hypothesis of
increased resveratrol-induced plasticity in hippocampus microstructure,
as shown in higher neurogenesis, microvasculature, and reduced glial
activation measured post mortem in older rats after resveratrol injections
(Kodali et al., 2015; Dias et al., 2016). In particular, MRI-derived hip-
pocampal MD (Weston et al., 2015) has been discussed as an inverse
measure of intact cellular barriers stemming from neurons, vasculature or
Figure 6. Differences in mean diffusivity between baseline and 6 months
follow-up measures of hippocampus subﬁelds. Values are z-transformed to reach
comparability between subﬁelds. Bars give means, error bars represent standard
error (S.E.). CA 1¼ Cornu Ammonis 1, CA 2/3¼ Cornu Ammonis 2/3, CA
4¼ Cornu Ammonis 4, DG¼Dentate Gyrus, Presub¼ Presubiculum, SUB
¼ Subiculum.
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astrocytes (den Heijer et al., 2012; Van Camp et al., 2012) and might
therefore be an even more sensitive plasticity measure compared to
volumetric measures. This has been supported by several studies in
beginning Alzheimer’s pathology and memory decline (Fellgiebel et al.,
2004; Kantarci et al., 2005; Muller et al., 2005; Muller et al., 2007).
However, in our study, there were no resveratrol-induced changes on
hippocampus MD, despite implementing recent advances in UHF MRI
and sensitive state-of-the-art preprocessing which integrated information
from two modalities and made use of the longitudinal design (Iglesias
et al., 2016). Yet univariate analyses suggested an increase in MD in the
presubiculum and subiculum subﬁelds in the current healthy sample
after only 6 months of time, which is possibly due to (un)healthy aging
effects. Therefore, our ﬁndings support the notion that MD measures
outperform volumetry in detecting subtle changes in hippocampus
microstructure. Again, the above-discussed lifestyle-changes might have
prevented us from observing signiﬁcant effects of resveratrol on MD.
With regard to resting-state fMRI, we could not replicate previous
ﬁndings of resveratrol-induced improvements in functional connectivity
of the hippocampus (Witte et al., 2014, Kobe et al., 2017). Disadvanta-
geous connectivity changes had previously been discussed as early signs
of functional reorganization that well precede structural and cognitive
changes (Sheline et al., 2010; Pievani et al., 2011; Prvulovic et al., 2011;
Kobe et al., 2017; Prehn et al., 2017). However, controlled studies on the
effects of plasticity-enhancing interventions on functional connectivity
measures are still scarce to date, and methodological limitations in
functional MRI might have reduced the potential to detect signiﬁcant
effects. For example, we noticed high head motion in >15% of our par-
ticipants, and the 2mm" 2mm" 2mm resolution of connectivity maps
did not allow analysis at the subﬁeld-level. This might have limited
statistical power to detect potential effects in our sample, even more so
when considering previous results of increased blood volume after
polyphenol supplementation that was restricted to the dentate gyrus
region of the hippocampus (Brickman et al., 2014). Upcoming im-
provements in UHF whole-brain fMRI (Robinson et al., 2015) might help
to further establish if resveratrol exerts beneﬁcial effects on hippocampus
connectivity.
Potential adverse events
Some minor adverse events were reported during our trial in both
groups, such as stomachaches, skin changes and mood changes. How-
ever, diarrhea was reported more often and with higher severity in the
resveratrol group and might be linked to the intervention. Especially as
adverse events caused by resveratrol have been described to affect the
abdomen (e.g. ﬂatulence, mild diarrhea), but at the same time to remain
moderate and reversible (Cottart et al., 2014). This is in line with several
studies including larger sample sizes that reported resveratrol to be safe
and well tolerated until a dose of 5 g per day (Almeida et al., 2009; Anton
et al., 2014; Cottart et al., 2014; Turner et al., 2015). Even though minor
adverse events were observed with doses higher than 0.5 g resveratrol
per day after consumption for several weeks and up to one year (Cottart
et al., 2014), this is still more than twice the amount of resveratrol in our
study. Yet, two participants belonging to the resveratrol group dropped
out, one due to a decrease in eyesight after 18 weeks of resveratrol intake
and the other one because of a skin rash that is unlikely to be caused by
resveratrol as it occurred ﬁve weeks after supplementation start. The
eyesight improved again after ending the treatment, whereas we do not
have further information regarding the skin rash. To our knowledge no
negative impact of resveratrol on eyesight has been reported yet. In
contrast, it has been reported to reduce oxidative damage in human
retinal pigment epithelial cells and therefore to inhibit cataract formation
(King et al., 2005; Zheng et al., 2010). Negative effects regarding the skin
have been reported previously, but do not have to be caused by resver-
atrol (Brown et al., 2010; Howells et al., 2011). In sum, our ﬁndings
implicate no major unintended effects of daily 200mg resveratrol intake
over the course of 6 months in healthy elderly. However, we cannot rule
out that resveratrol led to a sudden, transient decrease in eyesight in one
of our participants, a notion that future studies should take into account.
Limitations
Some limitations have been identiﬁed that might help to interpret our
results and to improve future studies. First, our study comprised of
healthy older adults with a wide BMI range. However, resveratrol seemed
to be effective especially in overweight and obese people. Additionally,
the study sample consisted mainly of highly educated participants with
good task-performance already at baseline. Therefore, there was little
scope to improve in cognitive and neuropsychological tasks. Further-
more, a different duration of the intervention or a change in dosage of
resveratrol could lead to other results. In future studies, participants
could be followed-up even longer after study cessation as post-
intervention effects might occur. This was however not feasible in our
study. In addition, the sample size might have been too small to detect
signiﬁcant effects in exploratory analyses including those of the ModBent
task, HbA1c, MRI and subgroups. Second, resveratrol pills also contained
quercetin to increase the bioavailability of resveratrol (De Santi et al.,
2000; Skroza et al., 2015). As quercetin itself is a bioactive compound, it
is not impossible that it affects cognition (e.g. memory recall) or other
outcomes itself (Nakagawa et al., 2016). Nevertheless, quercetin did not
have a signiﬁcant effect on neurocognitive functioning in a large
(n¼ 941) placebo-controlled, double-blind study with 12 weeks of
quercetin-supplementation (500mg or 1 g per day) (Broman-Fulks et al.,
2012), rendering a confounding effect of quercetin in the current study
unlikely. Third, the evaluation of compliance was largely based on
self-reported pill-diaries at interim and follow-up visit, and measures of
lifestyle behavior (physical activity, dietary intake) were based on
self-reported questionnaires. Self-reported data is always prone to
reporting errors according to social desirability (Herbert et al., 1995;
Figure 7. Functional connectivity differences of the
anterior and posterior left hippocampus: while the
anterior hippocampus (red) was more strongly con-
nected to the temporal lobe, the posterior hippo-
campus (blue) showed stronger connectivity to the
precuneus and angular gyrus. Hippocampus region of
interests (delineated in bold) derived from the mean
of all individual hippocampus masks transformed to
MNI space and thresholded at 0.2.
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Adams et al., 2005). Therefore, we cannot exclude that a low uninten-
tional compliance to the study instructions might have introduced
additional confounding. Data from resveratrol metabolites are yet difﬁ-
cult to interpret as they might rather reﬂect acute changes and might not
be suitable as long-term marker (Walle et al., 2011). Also, the change of
seasons from spring/summer at baseline to autumn/winter at follow-up
might have strongly inﬂuenced diet and physical activity of our sub-
jects. Also, holidays such as Thanksgiving, Christmas or Easter can
strongly inﬂuence eating behavior, underlining the importance to
incorporate information on seasons and holidays into the study design of
dietary interventions. This could mean to conduct the study within one
season (without holidays) or to design the studies in waves (e.g. wave 1
starts in summer, wave 2 in winter) and to control for those effects.
Strengths of our study include the interventional design, a well-
characterized sample and in-depths memory, blood samples and hippo-
campus phenotyping with cutting-edge UHF MRI.
Conclusions
This randomized interventional trial in healthy elderly with a wide
BMI range failed to show signiﬁcant effects of 6 months resveratrol
supplementation on verbal memory performance, while pattern recog-
nition performance tended to remain stable in the resveratrol group
compared to decreases after placebo (non-signiﬁcant trend). Additional
confounding factors might be study duration or administered dosage of
resveratrol, or possible ceiling effects in cognitive tasks, but also unfa-
vorable seasonal changes in lifestyle behavior in both groups, as indi-
cated by higher weight, body fat and sedentary behavior at follow-up
assessments. These changes were paralleled by increases in cholesterol in
the resveratrol group and increases in fasting glucose, inﬂammatory
markers and lower neurotrophins in both groups, factors known to be
detrimental for neuronal tissue and brain functions. Those negative ef-
fects might be due to resveratrol intake or lifestyle changes. Moreover,
though we could not detect resveratrol-induced plasticity in hippocam-
pus microstructure or functional connectivity, our ﬁndings further un-
derscore the feasibility to assess hippocampus microstructure at the
subﬁeld level to identify subtle changes in hippocampus microstructure
related to aging and/or lifestyle factors by implementing longitudinal
UHF MRI. Future studies incorporating additional memory tasks of
distinct sub-domains, a longer intervention period and larger sample
sizes, and a rigorous control of adjacent lifestyle changes might help to
determine whether resveratrol exerts beneﬁcial effects on memory and
the hippocampus in normal aging.
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Obesity has been associated with accelerated cognitive decline during ageing and an 
increased risk for dementia (Fergenbaum et al., 2009; Fitzpatrick et al., 2009; Gustafson 
et al., 2009; Whitmer et al., 2008). However, recent discussions are questioning this 
detrimental relationship (Prickett et al., 2015). A protective effect of midlife obesity was 
found in a large epidemiologic study (Qizilbash et al., 2015), whereas a meta-analysis 
showed that midlife obesity increases the risk of dementia (Albanese et al., 2017). 
Methodological difference and reverse causation could be the reasons for such 
conflicting results (Gustafson, 2015; Kivimäki et al., 2018). For example, some studies 
used either body mass index (BMI) or waist-to-hip ratio (WHR); their results suggested 
abdominal or central obesity, which is measured by WHR or waist circumference, is more 
detrimental for cognitive decline than global obesity measured by BMI (Gustafson et al., 
2009; Whitmer et al., 2008). Therefore, in order to assess the effect of body fat on 
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cognitive function in a large group of community-dwelling healthy adults, we used both 
BMI and WHR as indicators for adiposity (Study 1). 
To better understand cognitive changes, it is important to investigate obesity-related 
brain changes. Regarding to brain structure, high body fat has been associated with 
decreased total brain volume and regional grey and white matter volume (Willette and 
Kapogiannis, 2015). However, the findings regarding white matter volume are 
inconsistent; obesity was found to be associated with decreased as well as increased 
white matter volumes (Bobb et al., 2014; Driscoll et al., 2012; Karlsson et al., 2013; 
Walther et al., 2010). Because of the inconsistency, diffusion-weighted imaging (DWI), 
which assesses the microstructural architecture, has been considered to have higher 
agreements among studies on obesity and decreased directional property of white matter 
(Willette and Kapogiannis, 2015). However, a recent study reported a positive 
association between obesity and white matter microstructure (Birdsill et al., 2017). The 
conflicting results may be explained by the relative small–medium sample size (n = 15–
268) among the studies and limited statistical power for data-driven whole brain voxel-
wise analyses. Following the thought of increasing statistical power with bigger samples 
might be beneficial and more reliable, we investigated the link between body fat and 
white matter microstructure using a population-based sample of 1255 participants in 
Study 1. 
The obesity-related changes in the brain is considered to be a result of 
neuroinflammation. The neuroinflammation is likely caused by high fat intake- and 
excess adipose tissue-induced peripheral inflammation, which in turn leads to insulin 
resistance and hyperglycaemia; and these all together could also affect the hippocampus 
and result in memory inhibition (O’Brien et al., 2017; Pugazhenthi et al., 2016). A number 
of studies reported a negative association between obesity and hippocampal volume 
(Debette et al., 2011; Raji et al., 2010; Taki et al., 2008). However, others found a positive 
association (Widya et al., 2011) or no association (Bobb et al., 2014; Debette et al., 2011; 
Driscoll et al., 2012). This could be due to the fact that hippocampus comprises several 
subfields (cornu ammonis fields [CA1–4], the dentate gyrus [DG], and the subiculum), 
and these subfields have distinct functional properties (Deng et al., 2010; Strien et al., 
2009; Yassa and Stark, 2011). It has also been reported that the hippocampal subfields 
are affected by ageing differently (Malykhin et al., 2017). Because the hippocampus is 
highly susceptible to degenerative processes (Pfefferbaum et al., 2013; Raz et al., 2010) 
and possesses neurogenesis ability in adults (Eriksson et al., 1998), it is often a key 
target in intervention studies. 
Several studies indicate that lifestyle interventions can be effective to combat obesity 
and to restore cognitive functions (Siervo et al., 2011). A double-blind randomised 
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controlled trial of 1260 older individuals (aged 60–77 years) from the FINGER study 
showed that the intervention group obtained higher scores in a neuropsychological test 
battery compared to the control group after a 2-year multidomain intervention (diet, 
exercise, cognitive training, vascular risk monitoring) (Ngandu et al., 2015). Dietary 
nutrients that have anti-inflammatory or anti-oxidative effects, such as omega-3 fatty 
acids and polyphenols, have been associated with improved cognitive function and brain 
structural changes (Gómez-Pinilla, 2008; Huhn et al., 2015). Resveratrol is one type of 
polyphenols and occurs in variety of plants such as red grapes and blueberries (Baur et 
al., 2006). It has been reported to be associated with glucose metabolism and insulin 
sensitivity (Liu et al., 2014) as well as improved cognitive functions (Huhn et al., 2015; 
Marx et al., 2018). However, some studies reported no improvements in cognition after 
intervention (Köbe et al., 2017; Wightman et al., 2015). Besides the possibility that 
resveratrol does not affect cognition, another reason for these results could be that 
resveratrol is only effective in healthy ageing population (Evans et al., 2017; Witte et al., 
2014) but not in young (Wightman et al., 2015) or patient population (Köbe et al., 2017). 
Therefore, replication studies with healthy older adults could help to evaluate whether 
there is an effect of resveratrol on cognitive function. Following this idea, we have 
conducted a double-blind randomised controlled trial (Study 2) with comprehensive 
neuropsychological test battery to assess the effect of resveratrol using 60 elderly 
subjects. 
In Study 1, we applied whole brain voxel-wise analysis to explore the correlations 
between overall obesity (measured by BMI) or abdominal obesity (WHR) and white 
matter microstructure. We found a negative correlation between BMI as well as WHR 
and fractional anisotropy (FA), a measure of microstructural architecture, in multiple 
white matter tracts independent of confounding factors. We further explored the indirect 
link of obesity and cognitive dysfunction using mediation analysis. In the mediation 
analysis, an indirect path through obesity-associated clusters was considered. We found 
that although obesity had no direct effect on executive functions and processing speed, 
it affected cognitive performance through lower FA in callosal and associative fibre tracts. 
We found the correlation between obesity and memory performance was not mediated 
by FA in the selected white matter tracts. 
In Study 2, we conducted a randomised trial for the effect of resveratrol on memory 
performance and hippocampal structure. We found that intake of resveratrol did not show 
any beneficial effect on either glucose metabolism or cognitive performance. Neither 
volume nor mean diffusivity (MD), another measure of microstructural architecture, 
showed changes after the intervention compared to the placebo group. However, subtle 
ageing- or lifestyle-related changes in the MD of the hippocampus were detected. This 
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demonstrated that MD outperforms volumetric measures for detecting subtle changes of 
the hippocampus. The reason we could not observe any changes after resveratrol intake 
might be that this compound does not have an effect or that other lifestyle changes 
undermined the effect of resveratrol as neuroplasticity can be influenced by many factors. 
This thesis highlights that body fat is associated with lower FA in the white matter of the 
brain. This may indicate some widespread damage to the white matter; and mediation 
analysis indicates abdominal obesity is linked to poorer executive functions and 
processing speed through lower FA. Further this thesis shows that adding a dietary 
supplementation of resveratrol for six months does not improve memory or hippocampal 
structure in the present cohort of healthy adults with a large BMI range. Future studies 
should investigate longitudinal changes of body fat and brain structure in order to 
establish the causal relationship among obesity, white matter microstructure, and 
cognitive function. And more comprehensive lifestyle interventions combining diet, 
exercise, and cognitive training should be considered instead of one single approach to 
prevent and hopefully preserve obesity induced changes in cognition and in the brain.  
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8 SUPPLEMNTS	
8.1 Supplementary	Material	from	Publication	1	
 
Zhang et al. 2018, White matter microstructural variability mediates the relation between obesity and cognition in healthy adults
Appendix: Supplementary figures and tables
Fig. S1: In the SSE-image showing the residuals after tensor fitting, the chemical shift ("ghost")-artifact (red
arrows) can be seen as light-gray band-like structure in the occipital-parietal lobe. A, anterior, P, posterior, L,
left, R, right.
Fig. S2: Histograms showing the distribution of cognitive composite scores.
Fig. S3:  Association of higher body mass index (BMI) and lower white matter fractional anisotropy (FA)
adjusted for age, sex, volume of white matter hyperintensities, diabetes, APOE and hypertension (p < 0.05,
family-wise-error-corrected, n = 1088). This figure is layered on a T1-weighted image (coordinates according
to MNI152 template). Color bar represents t-value. Abbreviations: L, left; R, right.
1
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Zhang et al. 2018, White matter microstructural variability mediates the relation between obesity and cognition in healthy adults
Fig. S4:  Association of higher waist-to-hip ratio (WHR) and lower white matter fractional anisotropy (FA)
adjusted for age, sex, volume of white matter hyperintensities, diabetes, APOE and hypertension (p < 0.05,
family-wise-error-corrected, n = 1088). This figure is layered on a T1-weighted image (coordinates according
to MNI152 template). Color bar represents t-value. Abbreviations: L, left; R, right.
Fig. S5: Association of higher body mass index (BMI) and lower white matter fractional anisotropy (FA)
adjusted for age, sex, volume of white matter hyperintensities, and head motion (p < 0.05, family-wise-error-
corrected,  n = 1246).  This figure is  layered on a T1-weighted image (coordinates according to MNI152
template). Color bar represents t-value. Abbreviations: L, left; R, right.
Fig. S6: Association of higher waist-to-hip ratio (WHR) and lower white matter fractional anisotropy (FA)
adjusted for age, sex, volume of white matter hyperintensities, and head motion (p < 0.05, family-wise-error-
corrected,  n = 1246).  This figure is  layered on a T1-weighted image (coordinates according to MNI152
template). Color bar represents t-value. Abbreviations: L, left; R, right.
2
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Zhang et al. 2018, White matter microstructural variability mediates the relation between obesity and cognition in healthy adults
Table S1. Overview of raw cognitive subtest-scores indicating the available number for each subtest. Note
that phonemic verbal fluency was not available for participants < 60 years due to study design specifications.
Cognitive test n Scores
Verbal fluency semantic (no. of words) 1189 24.36 ± 6.21 (4-45)
Verbal fluency phonemic (no. of words) 611 13.16 ± 4.62 (1-27)
TMT part A (seconds) 1188 35.03 ± 13.04 (12-112)
TMT part B (seconds) 1184 82.95 ± 40.45 (24-300)
CERAD learning (no. of words) 1206 23.16 ± 3.80 (2-30)
CERAD delayed recall (no. of words) 1206 8.21 ± 1.73 (0-10)
CERAD recognition (no. of words) 1203 19.76 ± 0.60 (15-20)
Data are presented as mean ± SD (minimum-maximum).
Key: TMT, Trail Making Test; CERAD, Consortium to establish a registry for Alzheimer’s disease.
3
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8.2 Supplementary	Material	from	Publication	2	
 
 
Supplementary information 
Magnetic Resonance Imaging (MRI) Acquisition and Analysis 
Anatomical Imaging 
Anatomical MRI for hippocampal volumetry was acquired at a Siemens Magnetom 7 T 
system (Siemens Healthcare, Erlangen, Germany) using a 32-channel head array coil (NOVA 
Medical Inc., Wilmington MA, USA). High-resolution T1-weighted images were acquired 
using a MP2RAGE [1] protocol (repetition time (TR) = 5000 ms; inversion time (TI) 1/2 = 
900/2750 ms; echo time (TE) = 2.45 ms; image matrix: 320 x 320 x 240; voxel size 0.7 mm x 
0.7 mm x 0.7 mm; flip angle 1/2 = 5°/3°; parallel imaging using GRAPPA [2] with acceleration 
factor  =  2). T2-weighted imaging slabs perpendicular to the anterior-posterior axis of the 
hippocampus were acquired using a Turbo-Spin Echo Sequence (TR = 13000ms; TE = 14ms; 
image matrix: 384 x 384; 50 slices; voxel size: 0.5 mm x 0.5 mm x 1mm; refocusing flip angle 
= 120°; turbo factor = 8; parallel imaging using GRAPPA with acceleration factor = 2).  
The anatomical T1-weighted images were skull-stripped using CBS Tools [3]  and processed 
with the FreeSurfer image analysis suite version 6.0.0 (http://surfer.nmr.mgh.harvard.edu/) 
[4, 5]. First, T1-weighted images (baseline, follow-up) were processed cross-sectionally, then 
an unbiased template was created for each subject and used together with the data from 
each timepoint in the longitudinal stream (Reuter, et al. 2012), which increases reliability 
and statistical power in longitudinal designs. T2-weighted imaging slabs were manually 
reoriented to overlap with each timepoint’s normalized longitudinal T1-image (norm.mgz) in 
order to preserve the high in-plane resolution. Hippocampal subfield segmentation was 
performed using the T1- and T2-weighted images in a multimodal approach, which was 
initialized by the output of the longitudinal stream (Iglesias et al., 2015). 
Out of 13 subfields and structures segmented by the algorithm, we considered six main 
subfields (Cornu Ammonis 1, 2/3, 4, Dentate Gyrus, Presubiculum and Subiculum) for further 
analysis (Brickman, et al. 2014; Erickson, et al. 2011). Volumes were extracted from the 
multimodal segmentation and the longitudinal segmentation stream (Iglesias, et al. 2015) 
and averaged across hemispheres. See Figure S1 for an overview of intra- and intersubject 
variability of hippocampus subfield volumes.  
For the longitudinal anatomical analysis based on 7T MRI, 50 participants had complete data 
(n = 1 not MRI suitable at follow-up, n= 2 withdrew consent to undergo 7T MRI session at 
follow-up). Because of insufficient turbo spin echo (TSE) data quality at follow-up, another 
participant had to be excluded from the multimodal longitudinal subfield analysis 
(n (longitudinal) = 49; resveratrol n = 25, placebo n = 24).  
As there is evidence for hippocampal asymmetry in both healthy aging as well as 
neurodegenerative disease (Barnes, et al. 2005; Shi, et al. 2009) we checked for whole 
hippocampus asymmetry and hemisphere-by-time interaction in our sample before 
averaging hippocampal subfield volumes across hemispheres. In line with the literature (Shi, 
et al. 2009) we found the right hippocampus to be significantly larger than the left 
hippocampus (paired t-test at baseline: T= -4.9, p < 0.001 and follow-up: T= -4.0, p< 0.001) 
but did not find a significant hemisphere-by-time interaction (paired t-test between 
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hemispheres of the pre-post differences: T=-0.94, p=0.35). For our longitudinal analysis we 
therefore decided to average across hemispheres for each timepoint separately.  
 
 
Figure S1: Hippocampus subfield volumes pre-and post intervention. Colors represent 
individual participants (n = 49).  
 
Diffusion Weighted Imaging Analysis 
Diffusion weighted images (DWI) were collected at 7T with a single shot echo planar imaging 
(EPI) sequence (TR = 6000 ms; TE = 62.8 ms; image matrix = 128 × 128, 60 slices; voxel size = 
1.2 mm × 1.2 mm × 1.2 mm, 67 diffusion directions, b = 1000 s/mm2, parallel imaging using 
GRAPPA with acceleration factor = 2). The imaging slab was chosen to cover the bilateral 
hippocampus in all participants. In order to correct for image distortions, an additional 
volume with no diffusion weighting (b = 0) but with opposite phase-encoding direction was 
acquired.  
Preprocessing of diffusion weighted images was performed using FSL version 5.0.9. [6] and 
included estimation of susceptibility-induced off-resonance field based on b0-images in 
opposite phase-encode directions using  TOPUP  [7] as implemented in FSL [6]. The 
estimated susceptibility distortions were used to carry out corrections of susceptibility and 
eddy currents/movements with eddy tool [8]. Then, a tensor model was fitted to the 
corrected data and MD was calculated from the estimated diffusion tensors at each voxel. 
The resulting MD imaging slabs were registered to the cross-sectional T1-weighted 
MP2RAGE image in two steps. First, scanner coordinates were used to achieve a rough co-
registration using CBS Tools [3] as a plugin for MIPAV [9] and JIST [10] and then a non-linear 
registration of cerebral spinal fluid (CSF) masks from T1 and DWI was performed using 
ANTS’s symmetric normalization (SyN) algorithm, initialized by rigid and affine 
transformations [11]. CSF-masks were created from each subject’s MD image by 
thresholding at MD > 0.002 mm2/s and from T1-weighted images by using tissue 
segmentation implemented in FSL’s FAST. The whole brain CSF image was cropped to the 
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imaging slab of the DWI sequence before registration in order to improve the fit. The 
resulting transformation warp was then applied to the MD image. Hippocampal subfield 
labels based on the multimodal registration were brought from the longitudinal template 
space to the native space of each timepoint and then used to extract the median 
hemisphere-averaged MD of the six hippocampus subfields. MD values were restricted to be 
larger than zero and smaller than 0.002 mm2/s to reduce the noise introduced by imperfect 
segmentation and low signal-to-noise ratio.  
See Figure S2 for an overview of intra- and intersubject variability of hippocampus subfield 
volumes. 
Diffusion weighted imaging (DWI) data from one participant in the placebo group was 
further excluded based on an extreme mean diffusivity (MD) value (MD > 3rd percentile + 3 
* interquartile range) in the presubiculum and generally poor data quality (n (DWI) = 48, 
resveratrol n = 25, placebo n = 23). 
 
 
Figure S2: Mean Diffusivity of the subfields pre-and post intervention. Colors represent 
individual participants (n = 48).  
 
Resting State Functional Connectivity 
To achieve whole brain coverage resting state fMRI was performed on a 3T Siemens Verio 
Scanner with a 32 channel head coil. T1-weighted images were acquired using an MP-RAGE 
sequence and the Alzheimer's Disease Neuroimaging Initiative standard protocol (TI = 900 
ms; TR = 2300 ms; TE = 2.98 ms; image matrix = 256 × 240 x 176;  voxel size = 1.0 mm × 1.0 
mm × 1.0 mm; flip angle = 9°.  
Cortical reconstruction and volumetric segmentation was performed with FreeSurfer version 
5.3.0. [4, 5]. FreeSurfer brain masks were corrected using gcut or manual edits in order to 
improve the co-registration to functional and MNI space when necessary. Anterior and 
posterior hippocampus segmentation was performed using PCA-based automated rotation 
separating head and posterior section at 41.7% of the length of the longitudinal axis (Lerma-
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Usabiaga, et al. 2016). The resulting regions of interest were resampled to the resolution of 
the functional images (2mm isotropic).  
T2*-weighted functional images were acquired using a multi-band echo-planar-imaging 
sequence with the following parameters: TR = 1400 ms; TE = 30 ms; image matrix = 88 x 88; 
64 slices; voxel size = 2.3 mm x 2.3 mm x 2.3 mm; flip angle = 69°;  multiband factor = 4; 550 
volumes; total acquisition time, 12:49 minutes. Preprocessing with FSL, FREESURFER, ANTS 
and AFNI was implemented in a reproducible pipeline using Nipype (Gorgolewski, et al. 
2011) which is available to the public at https://github.com/fBeyer89/RSV_rsanalysis. 
After removal of the first five volumes in order to allow the magnetization to reach steady-
state, rigid body and boundary-based co-registration with six degrees of freedom of the 
functional scan to the anatomical image was estimated. Motion and EPI distortion 
corrections were calculated and jointly applied in a subsequent step to each volume of the 
functional scan. Then (i) six components explaining the highest variance from a singular 
value decomposition of white matter and cerebrospinal fluid time series (CompCor)[12], (ii) 
24 motion parameters (CPAC, (Friston, et al. 1995)), (iii) motion and signal intensity spikes 
(Nipype rapidart), and (iv) linear and quadratic signal trends were regressed from the data 
and bandpass-filtering between 0.01 and 0.1 Hz was applied. Hippocampus functional 
connectivity was estimated by correlating the mean time series in left and right posterior 
and anterior hippocampus with all other voxels in the brain. Subsequently, Fisher’s Z-
transform was applied and the connectivity maps were transformed to MNI space by the 
non-linear transform from subject to MNI space previously derived using the ANTS’s SyN 
algorithm [11]. The connectivity maps were then smoothed with a Gaussian kernel of 6 mm 
full-width-at-half-maximum.  
Frame-to-frame head motion was estimated by calculating framewise displacement (FD) 
according to (Power, et al. 2012). As motion is an important confounder in rs-fMRI we 
performed a sensitivity analysis following the approach described in Power, et al. (2014). 
After the identification of motion-corrupted volumes (DVARS > 0.5 and FD > 0.5 mm) using a 
publicly available quality checking script (https://github.com/poldrack/fmriqa) we 
performed the scrubbing procedure (replacement of identified volumes with data of similar 
frequency content, filtering and removal of identified volumes) as described in [13]. We then 
entered the scrubbed time series into the hippocampus connectivity pipeline. In total, 27 
baseline and 21 follow-up scans were scrubbed, with a mean number of 15 respectively 20 
scrubbed volumes in baseline and follow-up. All subjects had at least 8 minutes of resting 
state fMRI acquisition after removing volumes affected by motion. 
To verify the selection of anterior and posterior hippocampus ROIs, we calculated the within-
subject differences of anterior and posterior hippocampus connectivity for the right and left 
hippocampus separately using the baseline MRI data (n = 51 (one without MRI, six with 
strong head motion defined as mean framewise displacement (FD) > 0.5 mm or maximal 
FD > 3mm). For longitudinal analysis, n = 45 participants were eligible (one not MRI suitable 
at follow-up, three dropped out, two with strong head motion at follow-up). Out of these, 22 
were in the resveratrol and 23 in the placebo group. There was no significant difference in 
mean or maximal FD between groups. 
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Supplementary Table S1: Changes in diet and physical activity dependent on group. Data is 
given as mean ± SD (range). Diet was evaluated according to the food frequency questionnaire and 
data is given in kilocalorie intake per day. Physical activity was estimated with the International 
Physical Activity Questionnaire and evaluated according to standard procedure. Data is given in 
metabolic equivalents (MET) per week. 
 
 
Resveratrol (n = 27) Placebo (n = 26) 
Pre Post p, T(df)  
or p, Z 
Pre Post p, T(df) 
or p, Z 
Diet 
(kilocalorie 
intake per day) 
1969.7 ± 
924.2 
(474.02 – 
5196.25) 
2057.56 ± 
933.38 
(744.16 – 
5301.82) 
0.337, 
b 
1996.24 ± 
745.08 
(985.19 – 
4159.73) 
1867.08 ± 
801.98 
(875.21 – 
4410.72) 
0.131, 
b 
Physical 
Activity 
(MET/week) e 
13802.70 ± 
15526.72 
(417 – 
65382) 
7445.43 ± 
9539  
(0 – 48443) 
0.002, -
3.027, 
b 
9909.62 ± 
6782.1  
(1072 – 
32874) 
6858.58 ± 
4224.84  
(840 – 
17856) 
0.015, -
2.426, 
b 
Physical 
Activity 
(MET/week) f 
8385.05 ± 
5698.00  
(417 – 
22194) 
4985.95 ± 
3713.12  
(0 – 12426.0) 
0.011, -
2.549, 
b 
9335.02 ± 
6834.06 
(1072 – 
32874) 
6591.78 ± 
4078.06 
(840.00 – 
17856.0) 
0.052, -
1.947, 
b 
a) Dependent Sample T-Test, b) Wilcoxon Signed-Rank test. MET: metabolic equivalent. 
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Supplementary Table S2: Volume of whole hippocampus and subfields derived from the 
multimodal (T1-and T2-based) subfield segmentation before and after intervention/control 
period (n = 49). Data is given as mean ± SD. 
Mean Volume 
(in  mm3) 
Resveratrol (N = 25) Placebo (N = 24) 
Pre Post p, T(df) or  
p, Z 
Pre Post p, T(df) 
or p, Z 
Whole 
Hippocampus 
2939.96 ± 
320.48 
2925.42 
± 309.25 
0.35a 2937.43 ± 
263.91 
2948.83 
± 279.01 
0.49a 
Cornu Ammonis 1 581.25 ±  
66.22 
578.78 ± 
65.37 
0.61a 581.93 ± 
48.10 
581.60 ± 
54.57 
0.16b 
Cornu Ammonis 
2/3 
198.30 ± 
29.29 
199.43 ± 
30.15 
0.55a 199.19 ± 
24.50 
200.52 ± 
35.06 
0.28a 
Cornu Ammonis 4 218.65 ± 
25.87 
218.27 ± 
25.10 
0.82a 216.29 ± 
20.25 
215.31 ± 
21.65 
0.56a 
Dentate Gyrus 258.23 ± 
30.32 
257.89 ± 
29.08 
0.88a 254.76 ± 
24.88 
254.04 ± 
26.58 
0.71a 
Pre-Subiculum 259.49 ± 
28.94 
258.69 ± 
30.02 
0.74a 266.89 ± 
31.47 
271.10 ± 
34.27 
0.15a 
Subiculum 348.58 ± 
37.88 
348.11 ± 
35.67 
0.86a 349.08 ± 
31.76 
350.59 ± 
34.01 
0.63a 
a) Dependent Sample T-Test, b) Wilcoxon Signed-Rank test. 
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Supplementary Table S3: Mean diffusivity averaged over hemispheres of whole 
hippocampus and subfields before and after intervention/control period (n = 48). Data is 
given as mean ± SD.  
Mean diffusivity 
(in 10-3 mm2/s) 
Resveratrol (N = 25) Placebo (N = 23) 
Pre Post p, T(df) or 
p, Z 
Pre Post p, T(df) 
or p, Z 
Whole 
Hippocampus 
0.813 ± 
0.039 
0.826 ± 
0.037 
0.025 b 0.820± 
0.041 
0.833 ± 
0.041 
0.16a 
Cornu Ammonis 1 0.840 ± 
0.036 
0.849 ± 
0.041 
0.24b 0.848 ± 
0.052 
0.853 ± 
0.048 
0.66a 
Cornu Ammonis 2 
/ 3 
0.915 ± 
0.085 
0.909 ± 
0.069 
0.63a 0.938 ± 
0.090 
0.936 ± 
0.116 
0.92b 
Cornu Ammonis 4 0.836 ± 
0.081 
0.842 ± 
0.068 
0.2b 0.857 ± 
0.066 
0.866 ± 
0.090 
0.27b 
Dentate Gyrus 0.838 ± 
0.066 
0.845 ± 
0.047 
0.43a 0.856 ± 
0.058 
0.865 ± 
0.067 
0.26b 
Pre-Subiculum 0.782 ± 
0.079 
0.801 ± 
0.068 
0.098a 0.749 ± 
0.084 
0.781 ± 
0.058 
0.11b 
Subiculum 0.709 ± 
0.052 
0.719 ± 
0.056 
0.3b 0.697 ± 
0.067 
0.722 ± 
0.058 
0.064b 
a) Dependent Sample T-Test, b) Wilcoxon Signed-Rank test. 
 
Supplementary Information ModBent task 
The ModBent task was carried out according to Brickman et al. (2014)[15] without parallel 
versions as such (see [15], for details). Briefly, in part 1 of the task first a target figure is presented 
and after a short delay participants have to select the target, which is then presented together with 
a distractor figure. In part two of the ModBent participants see only one figure at a time and have 
to accept (picture was presented in part 1 of the task) or reject it (picture was not presented in part 
1 = foil figure). Part 1 consists of 41 trials with different complexities (degrees of the used Lissajous 
figures) and part 2 consists of 82 trials (41 acceptances and 41 rejections). 
The 41 trials in part 1 are based on different groups of pictures concerning the complexity of the 
Lissajous figures. For each level of complexity 5 pictures were available. The pictures were 
randomly shuffled for each participant. Then, in part 1 of the ModBent task at baseline, one 
picture was used as target image, while another one was selected as distractor and a third one as 
foil. In part 2 (at baseline) of the ModBent task always the target picture and the foil were shown.  
For the follow up version of the ModBent a new target and a new distractor were chosen, while 
the foil remained the same as in part one. The 41 trials in part 1 occur in randomized order 
concerning their complexity. All participants had the same number of trials for each difficulty. 
Thus, the ModBent task does not have parallel versions, but each participant has his/her own 
version for baseline and follow up. Please also see the picture attached to clarify the order of 
figures. 
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Supplementary Table S4: Overview of baseline and follow up values of depressive symptoms, perceived stress, sleep quality and diet (measured 
in consumed kilocalories per day and Mediterranean diet score). 
 
Parameter Resveratrol (n = 27) Placebo (n = 26) 
Pre Post p-value Pre Post p-value Depressive symptomsa 4.67 ± 3.2 3.96 ± 3.5 0.29e 5.46 ± 4.8 5.15 ± 4.6 0.45e 
Perceived stressb 8.93 ± 5.3 8.81 ± 5.4 0.84e 11.42 ± 6.2 10.78 ± 7.8 0.35e 
Sleep qualityc 5.19 ± 3.1 5.37 ± 3.1 0.61f 5.42 ± 2.9 5.80 ± 3.7 0.45f Total kilocalories /day 1970 ± 924 2058 ± 933 0.34f 1996 ± 745 1867 ± 802 0.13f 
Mediterranean diet Scored 4.6 ± 1.1 4.7 ± 1.4 0.91e 4.12 ± 1.6 4.19 ± 1.9 0.79e 
 
a) according to Beck’s Depression Inventory, b) according to Trierer Inventory for Chronic Stress (TICS), c) according to Pittsburgh Sleep Quality Index 
(PSQI), d) based on [14] e) Dependent Samples T-test, f) Wilcoxon Sign-Rank test 
 
Supplementary information antioxidant score: 
The “antioxidant-score” is similar to the Mediterranean diet score (Trichopoulou et al., 1995). The amount consumed of each food item in the respective 
groups was summed up (e.g. category 4: grams consumed of fresh fruit + grams consumed of processed fruit = grams consumed in category 4). Based on 
median splits for each category, participants were assigned 1 point, if they had a consumption above the median or 0, if below median. Then, the points for 
category 1 – 5 were summed up to receive the antioxidant-score. This approach did not reveal differences within or between groups in 
antioxidant/polyphenol content. Those conclusions were drawn within the limitations of our FFQ.  
 
 
Supplementary Table S5: Consumption in different composite food items measured with a semi-quantitative food frequency questionnaire. 
Polyphenol/Antioxidant Score Group Quantity_BL 
Between-group 
differences BL Quantity_FU 
Within-group 
differences BL-FU 
Univariate analysis 
(time*group) 
Category 1 Fruit juices RSV 6159 ± 17290 P=0.65 
Z=-0.45 
5668 ± 13.238 P=0.84 P=0.77   
  in ml/month placebo 5098 ± 17.388 6255 ± 21.777 P=0.59   
  vegetable juices RSV 559 ± 1478 P=0.74 
Z=-0.34 
146 ± 345 P=0.14 P=0.13   
  in ml/month placebo 340 ± 893 380 ± 1120 P=0.56   
  tea (black/green) RSV 1500 ± 2493 P=0.77 
Z=-0.30 
1942 ± 3627 P=0.11 P=0.10   
  in ml/month placebo 3470 ± 10.267 2922 ± 7996 P=0.53   
  coffee RSV 12.444 ± 5398 P=0.37 
Z=-0.90 
14.122 ± 6346 P=0.20 
P=0.16 
  
  in ml / month placebo 13.523 ± 15.799 10.932 ± 7834 P=0.68   
Category 2 beer RSV 2643 ± 5008 P=0.17 
Z=-1.36 
3315 ± 5947 P=0.84 
P=0.15 
  
  in ml/month placebo 3119 ± 3829 2678 ± 4306 P=0.061   
  Wine RSV 775 ± 566 P=0.55 
Z=-0.60 
938 ± 802 P=0.37 P=0.14   
  in ml / month placebo 1165 ± 1612 983 ± 1332 P=0.60   
Category 3 vegetables (fresh) RSV 1758 ± 1297 P=0.63 
Z=-0.48 
1557 ± 1545 P=0.15 P=0.11   
  in g/month placebo 1794 ± 1825 837 ± 707 P=0.020   
  vegetables (processed) RSV 1276 ± 1024 P=0.83 
Z=-0.21 
1545 ± 1301 P=0.27 P=0.46   
  in g/month placebo 1316 ± 1063 1364 ± 1059 P=0.53   
  legumes RSV 305 ± 216 P=0.71 
Z=-0.36 
350 ± 245 P=0.29 P=0.69   
  in g/month placebo 304 ± 263 317 ± 257 P=0.84   
Category 4 fruit (fresh) RSV 6266 ± 4382 P=0.65 
Z=-0.46 
6411 ± 5189 P=0.96 P=0.73   
  in g/month placebo 7090 ± 4820 6658 ± 5332 P=0.33   
  fruit (processed) RSV 465 ± 980 P=0.91 
Z=-0.12 
747 ± 1322 P=0.054 P=0.02   
  in g/month placebo 336 ± 521 211 ± 209 P=0.39   
Category 5 chocolate RSV 131 ± 135 P=0.23 
Z=-1.21 
125 ± 133 P=0.92 P=0.046   
  in g/month placebo 389 ± 565 208 ± 305 P=0.06   
  nuts RSV 163 ± 273 P=0.42 159 ± 188 P=0.46 P=0.59   
  in g/month placebo 124 ± 177 Z=-0.80 163 ± 421 P=0.63   Antioxidant Score Resveratrol (BL) Resveratrol (FU) Placebo (BL) Placebo (FU) Mean ± S.D (range) 2.41 ±1.2 (0-5) 2.59 ± 1.3 (0-5) 2.5 ±1.1 (0-4) 2.19 ±1.1 (0-4)      Wilcoxon Tests Within resveratrol group: p=0.37, z=-0.89 Within placebo group: p=0.27, z=-1.09 ANOVArm Time*group: p=0.2, time-effect: p=0.7   
TABLE S6: Overview AntiOx/Polyphenol-Score and comparison within and between groups 
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